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Abstract 
NaV1.7, a subtype of the voltage-gated sodium channel family that is highly expressed in 
peripheral sensory neurons, remains one of the most promising targets for the treatment of 
pain. However, despite compelling genetic evidence supporting a key role for NaV1.7 in 
regulating excitability of peripheral sensory neurons, the development of truly subtype-
selective inhibitors has been challenging. Here, we discuss complexities surrounding 
targeting NaV1.7 pharmacologically for treatment of pain and explore future opportunities for 
development of effective analgesic NaV1.7 inhibitors. 
 
Key words 
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1. Introduction 
Voltage-gated sodium channels (NaV) are crucial in the processes of action potential 
generation and propagation as they provide a path for influx of sodium ions (Na+) during the 
rising phase of an action potential. In humans there are nine α-subunit isoforms (NaV1.1-1.9) 
with distinct expression profiles. Several of these NaV isoforms have been implicated to have 
a role in pain, but none more so than NaV1.7, which has received considerable attention based 
on remarkable human phenotypes resulting from mutations in SCN9A, the gene encoding the 
pore-forming NaV1.7 α-subunit. Notably, loss of function mutations in SCN9A cause 
congenital insensitivity to pain, a rare human condition that leads to the inability to feel pain 
in the absence of other sensory impairments, other than loss of smell (anosmia). This makes 
NaV1.7 an attractive pain target, as the phenotype of congenital insensitivity to pain suggests 
that pharmacological inhibition of NaV1.7 could potentially treat a wide variety of pain types 
with little to no expected adverse effects. However, efforts to develop selective 
pharmacological inhibitors have been hampered due to the high level of homology between 
the NaV subtypes, and we therefore know surprisingly little about the therapeutic potential of 
selective NaV1.7 inhibitors. We review the evidence supporting the validity of NaV1.7 as a 
therapeutic target for pain, based on the findings from both genetic studies and functional 
assessment by NaV1.7 modulators described to date.  
 
2. Expression of NaV1.7 
Sensory neurons innervate peripheral tissues and provide us with the ability to sense touch, 
pressure, temperature and pain. They can be broadly classified into Aβ-, Aδ- and C-fibres 
based on conduction velocity, degree of myelination and size of the cell body. These neurons, 
whose cell bodies are found in the dorsal root ganglia, have a single axon with a peripheral 
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branch that terminates in the skin or viscera, and a central branch that terminates in the spinal 
cord. Located at the peripheral terminals of these neurons are a range of specialised ion 
channels and receptors that respond to noxious stimuli by causing small, localised sub-
threshold depolarisations known as generator potentials (Dubin and Patapoutian, 2010). 
 
NaV1.7, previously called PN1 or hNE, was initially identified as a peripheral neuron-specific 
sodium channel isoform highly expressed in sympathetic, dorsal root and trigeminal ganglia, 
but not at appreciable levels in the brain (Toledo-Aral et al., 1997) (Figure 1). The robust 
expression of NaV1.7 in postnatal and adult peripheral sensory neurons of all sizes has been 
systematically confirmed both in rodents, primates and humans (Ahmad et al., 2007; Black et 
al., 1996; Felts et al., 1997; Gould et al., 2000; Porreca et al., 1999; Sangameswaran et al., 
1997), with 63% of peripherin-positive dorsal root ganglion (DRG), 65% of IB4-positive 
neurons, 58% of CGRP-positive neurons and 15% of neurofilament-positive cell bodies 
exhibiting robust NaV1.7 immunolabelling (Black et al., 2012). This pattern of expression is 
consistent with high intensity staining observed in guinea pig DRG cell bodies giving rise to 
unmyelinated C-fibre polymodal nociceptors, followed by moderate staining in a significant 
proportion of high- and low-threshold myelinated Aδ neurons (Djouhri et al., 2003). In 
contrast, only some cutaneous myelinated Aα/β low-threshold mechanosensitive units, and no 
muscle spindle low-threshold mechanosensitive units expressed NaV1.7 (Djouhri et al., 2003; 
Rice et al., 2015). Expression of NaV1.7 extends to both central and peripheral projections of 
DRG neurons, with diffuse labelling evident in 27% of peripherin-positive axons of the 
sciatic nerve and at the nodes of Ranvier in 34% of Aδ fibres (Black et al., 2012). In the skin, 
NaV1.7 is expressed in free nerve terminals of both peptidergic and non-peptidergic 
intraepidermal nerve fibres, extending from the branching point of the dermal bundles to the 
terminal boutons (Black et al., 2012) where it is co-localised with NaV1.6, NaV1.8 and NaV1.9 
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(Persson et al., 2010). Similarly, NaV1.7 is also expressed in the central terminals of sensory 
neurons, specifically in laminae I and II of the dorsal horn where co-localisation with IB4, 
CGRP and synaptophysin suggests that NaV1.7 is involved in regulation of neurotransmitter 
release and transmission of nociceptive signals to higher brain centres (Black et al., 2012; 
Minett et al., 2012; Persson et al., 2010).  
 
NaV1.7 is also the predominant NaV isoform in olfactory neurons, with expression extending 
from the olfactory epithelium to the branches of the olfactory nerve (Ahn et al., 2011). 
However, NaV1.7 is absent in mitral and granule neurons receiving synaptic inputs from 
olfactory sensory neurons (Weiss et al., 2011). In the central nervous system, NaV1.7 is 
largely absent except for weak expression in the rodent pituitary gland, subfornical organ as 
well as the paraventricular hypothalamic (PVH), supraoptic and arcuate nuclei (Ahmad et al., 
2007; Morinville et al., 2007). In these brain regions, NaV1.7 is expressed in a population of 
hypothalamic neurons expressing agouti-related peptide (AGRP) and pro-opiomelanocortin 
(POMC) which have a well-established role in the regulation of feeding behaviour and 
energy homeostasis (Branco et al., 2016).  Notably, NaV1.7 expression in these areas is either 
absent or considerably lower in primate or human brain, consistent with the absence of any 
obvious central deficiencies, or altered body weight in conditions associated with NaV1.7 
gain- or loss-of-function. While hypothermia was reported in a patient with NaV1.7-
associated erythromelalgia, it is unclear at present whether this phenotype arises from deficits 
in hypothalamic function or simply reflects autonomic neuropathy or other unidentified 
causes (Black et al., 2013; Takahashi et al., 2007). 
 
In addition to the neuronal expression described above, NaV1.7 is also expressed in some 
non-neuronal cells. Consistent with the local vascular consequences of neurogenic 
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inflammation in the NaV1.7 gain-of-function conditions inherited erythromelalgia (IEM) and 
paroxysmal extreme pain disorder (PEPD), NaV1.7 is not only highly expressed by virtually 
all nerves innervating arterioles and arterio-venous shunts in the glabrous skin, but also in 
vascular myocytes and the vascular endothelium in human skin (Rice et al., 2015). In 
addition, NaV1.7 expression has been reported in β-cells of the pancreas, albeit its function in 
this tissue is unclear (Zhang et al., 2014). 
 
3. Functional properties of NaV1.7 
The expression pattern and subcellular localization of NaV1.7 suggest a critical role in 
determining the excitability of peripheral sensory neurons, a function that is supported by 
several unique gating properties of the channel. Notably, the development of closed-state 
inactivation is substantially slower for NaV1.7 compared with other NaV subtypes (Cummins 
et al., 1998; Rush et al., 2007). Functionally, this renders NaV1.7 less likely to inactivate 
during the sub-threshold depolarisations (or generator potentials) originating from stimulus 
transducers such as transient receptor potential channels in sensory nerve endings. 
Consequently, NaV1.7 remains available for activation and production of ramp currents in 
response to slow depolarisations (Cummins et al., 1998; Rush et al., 2007). These properties 
position NaV1.7 as an amplifier of generator potentials and a threshold channel for setting the 
sensitivity of action potential firing (Black et al., 2012; Rush et al., 2007). Indeed, although 
loss of NaV1.7 does not affect the peak amplitude of action potentials in DRG neurons, it was 
found to slow the rising phase of the action potential, with 30% of DRG neurons from NaV1.7 
knockout animals failing to generate action potentials (Raouf et al., 2012).   
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Expression of NaV1.7 along axonal projections of unmyelinated and myelinated peripheral 
fibres suggests an additional contribution to action potential propagation. However, while 
NaV1.7, along with other tetrodotoxin sensitive (TTX-s) channels, rapidly activates in 
response to depolarisation, it is also characterised by rapid and relatively hyperpolarized 
inactivation as well as slow recovery from inactivation or slow repriming (Herzog et al., 
2003). Thus, while NaV1.7 contributes to the initiation and upstroke of action potentials in 
nociceptors, it is likely unable to sustain repetitive action potential firing, with conduction of 
rapidly firing A- and C-fibres likely mediated by NaV1.6 and NaV1.8 (Black et al., 2013; 
Rush et al., 2007), respectively. However, the functional contribution of NaV1.7 to action 
potential propagation remains to be conclusively defined. In contrast to axonal conduction, 
neurotransmitter release both in peripheral as well as central projections of sensory neurons 
likely relies on a contribution of NaV1.7 to local electrogenesis (Alexandrou et al., 2016), 
corroborating a key role for NaV1.7 in generation and transmission of nociceptive signals.    
 
In the rodent central nervous system, NaV1.7 contributes a persistent sodium current in 
hypothalamic AGRP, POMC, and PVH neurons – three neuronal types involved in appetite 
regulation and hunger (Sternson et al., 2005) – that specifically prolongs excitatory 
postsynaptic potentials and enables efficient integration of synaptic input. Similar integration 
of sub-threshold depolarizations requiring persistent sodium currents has also been described 
in lamina I neurons of the spinal dorsal horn (Prescott and De Koninck, 2005). Although the 
contribution of NaV1.7 to this effect has not been assessed to date, it is possible that it plays 
an analogous role of integrating synaptic input in the nociceptive pathway in the spinal cord. 
 
4. NaV1.7 as an analgesic target: genetic evidence 
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4.1 Congenital Insensitivity to Pain and NaV1.7 
NaV1.7 gained particular attention as a putative pain target after the seminal discovery that 
mutations in SCN9A, the gene encoding NaV1.7, underlies the condition Congenital 
Insensitivity to Pain. There is a long history of reports of patients with a seemingly hereditary 
inability to respond to normally painful stimuli in the expected manner. Initial terms to 
describe such individuals include ‘congenital general pure analgesia’ (Dearborn, 1932), 
‘sensory syndrome’ (Ogden et al., 1959), ‘congenital universal insensitiveness to pain’ (Ford 
and Wilkins, 1938), ‘congenital universal indifference to pain’ (Boyd and Nie, 1949), and 
‘congenital absence of pain’ (Nagasako et al., 2003; Winkelmann et al., 1962). These 
descriptions are based on the sensory-discriminative, affective-motivational and cognitive-
evaluative components of pain but reveal little of the molecular mechanisms contributing to 
these conditions. 
 
Historically, the term congenital insensitivity to pain was used predominantly to describe the 
inability to sense the type, intensity, and quality of painful stimuli due to malfunction of the 
peripheral nervous system that was manifested in gross sensory abnormalities and peripheral 
neuropathies (Nagasako et al., 2003). In contrast, congenital indifference to pain implied the 
absence of (measurable) deficits in signal transmission and sensory neuron function and 
attributed the absence of pain to a presumably affective deficit (Landrieu et al., 1990; Ogden 
et al., 1959). However, while central lesions undeniably can be associated with a lack of pain 
and inadequate emotional response to nociceptive stimuli (Berthier et al., 1988), it seems 
likely that failure to diagnose altered peripheral sensory neuron function in the majority of 
cases labelled as congenital indifference to pain arise from the lack of gross histopathological 
changes and inadequate diagnostic tools.  
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Accordingly, these conditions are more accurately classified amongst the hereditary sensory 
and autonomic neuropathies (HSAN), which are further sub-categorized based on the mode 
of inheritance, onset, course, symptoms, prognosis, populations of neurons or axons affected, 
and the genetic basis of the condition (Axelrod and Hilz, 2003; Dyck et al., 1983; Dyck and 
Ohta, 1975; Rotthier et al., 2012; Yuan et al., 2013). In recent years, thanks to the decreasing 
cost and increasing access to efficient genome/exome sequencing, classification of hereditary 
sensory and autonomic neuropathies has been extended to include the genetic basis of these 
disorders, where known (Table 1). 
 
SCN9A is causally associated with the development of at least two, likely distinct, phenotypic 
presentations: HSAN IID and Channelopathy-associated Insensitivity to Pain (Table 1). 
Frameshift deletions in SCN9A were found in three patients with hereditary sensory and 
autonomic neuropathy type II D (HSAN2d), which presents with incomplete or progressive 
loss of pain and thermosensation as well as varying degrees of hypohidrosis (diminished 
sweating), hearing loss and autonomic dysfunction (Yuan et al., 2013). In contrast, the 
clinical presentation of congenital insensitivity to pain (CIP) or channelopathy-associated 
insensitivity to pain is characterised by complete congenital analgesia that usually manifests 
as painless injuries including burns, fractures and injuries particularly of the lips and tongue, 
but no autonomic dysfunction (Table 2). Anosmia or hyposmia appear to be consistently 
present, though they are not always reported by patients. Mechanosensation, proprioception 
and the ability to distinguish cold and hot, vibration, pinprick, sharp, dull and pressure stimuli 
are typically reported as intact, albeit systematic quantitative sensory testing has not been 
conducted in the majority of patients. Accordingly, some deficits in thermosensation or 
altered thermal thresholds have been reported in a small number of patients (Nilsen et al., 
2009; Ramirez et al., 2014; Staud et al., 2011), although it is unclear whether closer 
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investigation would unearth additional phenotypic changes in other patients. Similarly, 
although motor conduction and tendon reflexes are typically normal, several cases with 
decreased corneal reflexes and decreased sensory nerve conduction velocity or action 
potential amplitude have been reported (Cox et al., 2010; Nilsen et al., 2009; Peddareddygari 
et al., 2014; Ramirez et al., 2014; Shorer et al., 2014; Staud et al., 2011). While the causality 
and significance of these observations is currently unclear, the absence of gross conduction 
changes argues for a perhaps a minor role of NaV1.7, or a degree of functional redundancy, in 
action potential propagation of sensory neurons. Interestingly, while heat nociception was 
absent in all patients reported to date, it is unclear whether cold nociception is also affected to 
the same degree. NaV1.8 expressed at peripheral sensory nerve endings is crucial for 
generating action potentials during cooling as NaV1.7 enters a state of slow inactivation 
(Zimmermann et al., 2007). Thus, absence of noxious cold pain in congenital insensitivity to 
pain would suggest functional deficits including decreased action potential propagation or 
decreased transmission of nociceptive signals at the spinal level, rather than altered action 
potential generation at sensory nerve endings. This notion is consistent with loss of synaptic 
transmission in the olfactory glomeruli in NaV1.7-/- animals, where axonal action potential 
initiation and propagation is normal, but anosmia arises from complete loss of 
neurotransmitter release (Gingras et al., 2014; Heimann et al., 2013; Weiss et al., 2011). 
Alternatively, it is plausible that the multimodal loss of nociception characteristic of 
congenital insensitivity to pain requires loss of NaV1.7 at peripheral sensory nerve endings, 
axons, as well as central terminals, and loss of NaV1.7 function at any of these sites in 
isolation may not recapitulate a pan-modality pain-free phenotype.  
 
 Interestingly, although gain-of-function NaV1.7 mutations have been associated with pruritus 
(Devigili et al., 2014; Snyder et al., 2014), and CIP patients reportedly remain ticklish, it is 
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unclear whether congenital insensitivity to pain also encompasses congenital insensitivity to 
itch. Although the axon reflex flare and response to intradermal histamine - where assessed – 
is typically normal, the response to pruritogenic or algogenic chemicals has not been 
systematically evaluated in these patients. 
 
Most of the mutations associated with congenital insensitivity to pain described to-date cause 
channel truncations and mis-splicing mutations which either alone, or in combination with 
defective trafficking, lead to a complete loss of functional NaV1.7 (Table 2). The complete 
lack of nociceptive responses associated with these loss-of-function mutations highlight some 
important characteristics of NaV1.7 function in humans; including the absolute requirement 
for this isoform for transmission of nociceptive signals to higher brain centres, the lack of 
interference of truncated Nav1.7 channel proteins with the function of other isoforms, as well 
as the apparent redundancy of NaV1.7 in sympathetic neurons and non-nociceptive sensory 
neurons. However, the extreme phenotype associated with these mutations raises questions 
about the level of reduced NaV1.7 function required to achieve insensitivity to pain, and 
whether it is possible to achieve graded analgesia, rather than all-or-none anti-nociception, 
with a reduction in NaV1.7 function. Recently, a number of NaV1.7 mutations that retained 
some function were described in patients who appeared phenotypically identical to patients 
with loss-of-function mutations (Emery et al., 2015). While one of these mutations (A1236E) 
led to a near-complete (~90%) inhibition of current, two mutations (L1831X and W1775R) 
were associated with significant, though incomplete, reduction in peak current as well as a 
depolarizing shift in channel activation (Emery et al., 2015).  These mutations are particularly 
noteworthy because incomplete channel block by highly NaV1.7-selective gating modifiers 
has been proposed to contribute to a lack of analgesic efficacy (Minett et al., 2015). However, 
in light of the complete analgesia reported in patients with these missense mutations, this 
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explanation seems implausible, albeit it should be noted that the true level of NaV1.7 function 
in patients with compound heterozygous mutations can be difficult to estimate. It is clear, 
however, that substantial loss of NaV1.7 function is required for analgesia, as heterozygous 
carriers of null-mutations appear asymptomatic. Sensations elicited by noxious stimuli in a 
case of reported “partial congenital insensitivity to pain” due to a 1 bp splice donor deletion 
and a C1719R missense mutation remain minor (Staud et al., 2011), and although no 
biophysical analysis was performed, there seems to be no linear continuum of diminished 
pain mirroring diminished NaV1.7 function. 
 
4.2 Loss of NaV1.7 function is associated with upregulation of endogenous opioids 
A link between upregulation of endogenous opioids and congenital insensitivity to 
pain (CIP) was first reported in 1977, when intravenous administration of the nonselective 
opioid receptor antagonist naloxone was observed to result in a normalisation of nociceptive 
reflex thresholds in a patient with CIP (Dehen et al., 1977). Although a causal link to NaV1.7 
cannot be definitively assigned retrospectively, the clinical presentation – including 
preservation of thermosensation and mechanosensation as well as intact sensory action 
potentials from sural nerve, intact reflexes and histamine response – is consistent with 
channelopathy-associated congenital insensitivity to pain. Interestingly, although treatment 
with naloxone reduced the nociceptive reflex threshold from 45 mA to levels approaching 
normal controls (10 mA), no sensation of pain was reported by the patient (Dehen et al., 
1977; Dehen et al., 1978; Willer et al., 1978). It is possible that this absence of reported pain 
reflects a lack of the learnt emotional response to nociceptive stimuli, or that naloxone 
treatment leads to an incomplete normalisation of nociception. Naloxone treatment also 
normalised somatosensory potentials evoked by stimulation of the contralateral medial nerve 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
14 
 
of the wrist (Nuno-Licona et al., 1981) and the tooth pulp in additional (presumptive) CIP 
patients (Yanagida, 1978; 1979). 
However, this phenomenon was only recently linked to loss-of-function mutations in 
SCN9A, with both NaV1.7 knockout mice as well as a Nav1.7-null patient regaining 
sensitivity to noxious stimuli after treatment with naloxone (Minett et al., 2015). Naloxone 
normalized the reduced warm detection threshold of this patient, although pain intensity 
induced by a noxious thermal stimulus was consistently lower than the response elicited by 
the same stimulus in normal subjects. 
 
The reversal of antinociception in Advil-Cre NaV1.7 knockout mice by naloxone was 
attributed to the upregulation of pENK mRNA in dorsal root ganglion neurons (DRG), and 
met-enkephalin at the protein level; an effect that was specific to loss of functional NaV1.7, as 
no upregulation of endogenous opioids at the mRNA level was observed in NaV1.8 or NaV1.9 
knockout mice (Minett et al., 2015). A mechanistic link between loss of NaV1.7 function and 
upregulation of endogenous opioids has not yet been definitively established but may involve 
sodium-dependent transcription factors (Minett et al., 2015), although it remains to be 
explored why this would be restricted to sodium influx through NaV1.7 but not other sensory 
neuron isoforms including NaV1.8 and NaV1.9. 
 
Notably, the link to upregulation of pENK was not confirmed in the CIP patient 
examined in the most recent study (Minett et al., 2015; Nilsen et al., 2009), and normal levels 
of met-enkephalin-like substances were reported in a previous study describing a case of 
naloxone-sensitive congenital insensitivity to pain (Cesselin et al., 1984). Similarly, no 
change in endogenous levels of β-endorphin was found in naloxone-sensitive (Dehen et al., 
1986) CIP, while upregulation of calcitonin, total CSF opioid peptide content, and variable β-
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endorphin levels was reported in patients with naloxone-resistant congenital insensitivity to 
pain (Fabbri et al., 1983; Manfredi et al., 1981; Pasi et al., 1982). In addition, 
intracerebroventricular injection of cerebrospinal fluid obtained from a patient with 
congenital indifference to pain elicited naloxone-sensitive analgesia in rats, supporting a 
causal involvement of upregulated endogenous opioids in insensitivity to nociceptive stimuli 
(Fabbri et al., 1984). However, the pain-free phenotype of this patient was not reversible with 
naloxone, raising questions about the nature and causal contribution of endogenous opioids to 
the clinical presentation of congenital insensitivity to pain in humans.  
 
It is currently unclear whether cases of congenital insensitivity of pain that do not respond to 
naloxone are also based on NaV1.7 mutations, or whether these may have had other genetic 
causes that lead to similar clinical presentation (Fabbri et al., 1983; Manfredi et al., 1981; 
Pasi et al., 1982). Thus, systematic evaluation of the contribution of endogenous opioids to 
congenital insensitivity to pain causally associated with mutations in SCN9A remains to be 
conducted.  
 
4.3 Inherited Erythromelalgia and NaV1.7 
Genetic evidence for a crucial role of NaV1.7 in pain pathways was first described in patients 
with a gain-of-function mutation causally linked to inherited erythromelalgia (IEM, also 
called primary erythermalgia), a rare autosomal dominant disease characterised by severe 
pain affecting the extremities (Figure 2) (Yang et al., 2004). It should be noted that prior to 
the identification of the genetic cause of IEM, careful distinction between erythermalgia and 
erythromelalgia, an independent disease entity closely associated with thrombocythermia and 
responsive to aspirin, was made, although this terminological differentiation is rarely made 
today. 
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Clinically, IEM presents as painful episodes or attacks of varying duration that can be 
triggered by a range of stimuli and activities, including warmth, exercise, high humidity, cold 
or hot weather, clothes, infections and stress. The quality of IEM-associated pain is typically 
described as burning and frequently accompanied by symmetrical vasodilation and reddening 
of the affected limbs. The pain attacks are relieved by cooling, which can become compulsive 
and result in skin lesions (Michiels et al., 2005). Other autonomic symptoms, including 
gastrointestinal dysfunction and orthostatic hypotension are – in contrast to patients with 
NaV1.7-associated small-fibre neuropathy (Faber et al., 2012a) – rarely reported (McDonnell 
et al., 2016). IEM often first presents in early childhood, although variants of the condition 
can manifest with delayed onset in the second decade of life or even as adults. A range of 
mutations, located throughout domains I to IV of NaV1.7, have been causally linked to IEM 
(Figure 2, Table 3). The majority of these mutations consistently lead to enhanced activation, 
with variable effects on inactivation and other physical properties of the NaV1.7 channel. The 
observed hyperpolarizing shifts in activation, depolarizing shifts in steady-state inactivation, 
slowing of deactivation and enhanced ramp or persistent currents hypothetically all augment 
neuronal responses to small stimuli, which may explain the clinical presentation of IEM. 
However, the functional consequences of these mutations depends, at least in part, on the ion 
channel expression profile of affected neurons. In sensory neurons expressing NaV1.8, these 
mutations cause hyperexcitability, presumably because NaV1.8 has a relatively depolarised 
voltage-dependence of activation and thus remains available for sustained action potential 
firing at depolarised membrane potentials (Rush et al., 2006). In contrast, in sympathetic 
neurons lacking NaV1.8, the same mutation also depolarises resting membrane potential, but 
NaV1.3 and NaV1.6 which are also expressed in these neurons would be expected to 
progressively inactivate, resulting in a decrease in excitability (Rush et al., 2006). 
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For practical reasons, the electrophysiological characterization of NaV1.7 mutations 
associated with IEM are typically carried out at room temperature. Given the close 
association of IEM symptoms with temperature, profound effects of heating or cooling on the 
biophysical properties of the channels could be expected. Interestingly, cooling to 10 °C has 
previously been described to enhance slow inactivation of NaV1.7, a phenomenon which was 
presumed to be the basis for cooling-induced loss of excitability of TTX-sensitive fibres 
(Zimmermann et al., 2007). Given that several IEM mutations already display enhanced slow 
inactivation at room temperature (Table 3), it would be particularly interesting to assess 
whether slow inactivation is further enhanced in these mutants with similar temperature-
dependence. Cooling-induced effects have been assessed for L858F (Han et al., 2007) and 
indeed showed normalization of the shift in voltage-dependence of activation, although ramp 
currents increased, most likely due to decreased deactivation which was similar for wild-type 
and mutant channels. Accordingly, the analgesic effect of cooling may be caused by 
alterations in the gating properties of other channels that contribute to excitability of 
peripheral nerve endings in the skin, rather than direct effects on activation or inactivation 
properties of NaV1.7. Interestingly, re-assessment of the I848T mutant channel at 35 °C 
(compared to 25 °C) revealed normalization of the shift in activation, while the depolarizing 
shift in the voltage-dependence of inactivation was exacerbated (Wu et al., 2013).  
In addition, the enhanced excitability of DRG neurons expressing NaV1.7 channels with the 
IEM mutation A1632G was exacerbated at increased temperatures, however, the specific 
effects of temperature on channel gating were not reported. Given that the A1632G mutation 
is associated with both a hyperpolarizing shift in the voltage-dependence of activation as well 
as a depolarizing shift in the voltage-dependence of inactivation (similar to I848T), but is 
associated with symptoms consistent with IEM (Yang et al., 2016), the presumed close link 
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between the clinical presentation of IEM and hyperpolarising shifts in the voltage-
dependence of activation may need to be revisited (Eberhardt et al., 2014). These 
observations potentially account for the clinically-observed sensory neuron hyperexcitability 
of patients with the described mutations and illustrate the importance of assessing channel 
function under more physiologically representative conditions. 
 
4.4 Paroxysmal Extreme Pain Disorder and NaV1.7 
Paroxysmal Extreme Pain Disorder (PEPD) - a condition formerly known as Familial Rectal 
Pain Syndrome - is associated with gain-of-function mutations of NaV1.7 located 
predominantly in domains III and IV (Figure 2). In contrast to IEM, the clinical presentation 
of PEPD is characterised by excruciating pain and erythema localised to the rectum, ocular or 
submandibular region that can be triggered by noxious or innocuous stimuli such as 
defecation, eating, yawning, warmth and emotional factors. In severe episodes, pain can 
spread to the lower extremities and may be associated with bradycardia, asystolic syncope, 
lacrimation, rhinorrhoea and tonic nonepilpetic seizures (Fertleman et al., 2006).  
 
The majority of mutations in SCN9A associated with PEPD lead to predominant effects on 
fast inactivation of the channel, resulting in enhanced persistent, ramp and resurgent currents 
that in turn increase excitability of sensory neurons and impair channel closure during action 
potential firing (Dib-Hajj et al., 2008b; Fertleman et al., 2006; Jarecki et al., 2008). 
Intriguingly, while IEM is closely associated with thermal triggers and typically alleviate by 
cooling, PEPD is more often triggered by mechanical stimuli, and relief is rarely afforded by 
cooling. The mechanistic reasons underlying these differences in presentation are currently 
unclear, although all PEPD mutations assessed to date are associated with resurgent currents 
that in turn may be determined by effects on the inactivation time constant (Theile et al., 
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2011). Alternatively, enhanced slow inactivation, which intuitively should lead to decreased 
channel availability and thus decreased neuronal excitability, may oppose the development of 
resurgent currents in the case of some IEM mutations (Hampl et al., 2016). However, effects 
on slow inactivation are inconsistent, raising questions about the physiological importance of 
this parameter in either IEM or PEPD (Table 3). While the effect of IEM mutations on 
resurgent currents has not been assessed consistently, at least two mutations (I136V and 
I823R) also cause delays in inactivation in the absence of symptoms consistent with PEPD or 
a mixed phenotype, suggesting that the clinical picture of PEPD and IEM is likely caused by 
more complex effects on the electrophysiological properties of NaV1.7. 
 
Although low levels of NaV1.7 expression in the CNS of humans have been reported, none of 
the patients bearing gain-of-function mutations present with central nervous system 
abnormalities. Indeed, even in cases of PEPD that present with tonic seizures, epileptiform 
CNS abnormalities are typically lacking (Choi et al., 2011). This re-asserts NaV1.7-mediated 
conditions as molecular lesions arising in the peripheral nervous system and suggests that 
central NaV1.7 plays only a minor pathophysiological role. 
 
4.5 SCN9A polymorphisms and pain 
While the phenotypic effects of gain- and loss-of-function mutations at NaV1.7 are profound, 
the contribution of SCN9A polymorphisms to pain susceptibility is less clear. The rs6754031 
SNP was associated with fibromyalgia, with the GG genotype being positively correlated 
with increased pain (Vargas-Alarcon et al., 2012); while initial reports that the non-
synonymous SNP rs6746030, causing the R1150W mutation, is associated with increased 
experimental pain and positively correlated to pain scores in osteoarthritis (Reimann et al., 
2010) could not be validated by subsequent studies (Holliday et al., 2012; Valdes et al., 
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2011). Similarly, idiopathic small fibre neuropathy was associated with a range of NaV1.7 
mutations, including I720K, M1532I, I228M, I739V, D623N, M932L/V991L and R185H in 
some patients, while 1908G, M932L/V991L and the intronic variant rs74449889 occurred at 
higher frequency in chronic painful diabetic neuropathy (Faber et al., 2012a; Li et al., 2015). 
The functional consequences of some of these mutations (Table 3) are consistent with gain-
of-function effects that may be causally linked to these painful conditions, although it is 
notable that none of the effects on electrophysiological parameters closely resembles changes 
typically observed either in PEPD or IEM (Faber et al., 2012a). However, in light of the 
effects of increased temperature on the biophysical properties of Nav1.7 and in particular the 
IEM mutations described above, the functional consequences of the potential small fibre 
neuropathy associated mutations may not be evident under the conditions used for their 
characterisation.  
 
5. Functional consequences of SCN9A knock out in mice   
Initial efforts to establish a global Scn9a deletion mutant failed due to the death of pups 
shortly after birth, which was unexpected given that human SCN9A non-sense mutations are 
not lethal. This led to the generation of several conditionally silenced Scn9a (NaV1.7) strains 
using Cre-Lox recombination, allowing site specific loss of functional NaV1.7 driven by a 
tissue-specific promoter, which overcame the lethality caused by global deletion (Minett et 
al., 2012; Nassar et al., 2004) (Table 4). Specifically, loxP sites were inserted in introns 
flanking exons 14 and 15 which encode most of domain II, leading to a subsequent loss of 
channel function in a Cre recombinase-specific manner (Nassar et al., 2004).  
The promoters used to achieve tissue-specific expression of Cre recombinase are NaV1.8, 
causing deletion in nociceptive neurons; Advillin, causing loss of functional NaV1.7 in all 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
21 
 
sensory neurons; and Wnt1, causing loss of functional NaV1.7 in neurons originating from the 
dorsal neural tube, including all sensory and sympathetic neurons. It later became apparent 
that NaV1.7 is the primary NaV subtype expressed in olfactory neurons (Ahn et al., 2011), 
providing an explanation for the lethality of global Scn9a deletion in mice, as pups are born 
blind and require a sense of smell in order to feed. Nonetheless, a global NaV1.7 knockout 
mouse strain has recently been generated, overcoming the anosmia and subsequent death of 
pups by hand rearing with an artificial mouse milk formula (Gingras et al., 2014). This global 
knockout strain recapitulated the human CIP phenotype, with mice unresponsive to 
nociceptive mechanical and thermal stimuli (Gingras et al., 2014). Interestingly, tissue 
specific deletion of NaV1.7 in NaV1.7Nav1.8 (nociceptor specific) and NaV1.7Advil (all sensory 
neurons) strains did not reproduce the CIP phenotype, with mice remaining responsive to 
noxious thermal stimuli. Surprisingly, it wasn’t until NaV1.7 function was abolished in both 
sensory and sympathetic neurons in NaV1.7Wnt1 mice that the CIP phenotype was reproduced, 
providing evidence that NaV1.7 in sympathetic neurons plays a role in pain, although their 
precise contribution to acute nociception remains unclear  (Minett et al., 2012; Nassar et al., 
2004).  
Consistent with particularly high expression of NaV1.7 in nociceptive C-fibres, global loss of 
functional NaV1.7 lead to a decrease in mechanically evoked C-fibre firing ex vivo that 
reached statistical significance at high stimulus intensities (Gingras et al., 2014). While this 
rather modest phenotypic effect is somewhat surprising, and difficult to reconcile with the 
profound lack of pain responses to nociceptive stimuli, one caveat is that C-fibres that were 
rendered unexcitable by loss of NaV1.7 would be unavailable for recordings. Alternatively, 
myelinated A-fibres may also contribute to behavioural responses to noxious mechanical 
stimuli, and the effect of NaV1.7 loss on these fibre types remains to be determined. A clue is 
perhaps evident from observations that mechanical sensitivity is reduced in the hairy skin of 
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the abdomen in NaV1.7Advil and NaV1.7Wnt1 conditional gene silencing mice, but not in shaved 
or glabrous skin in the same animals (Minett et al., 2014a). 
 
Interestingly, although attenuated, not all pain behaviours were abolished in the global 
NaV1.7 knockout mice, with some pain behaviours still observed after local administration of 
the nociceptive chemicals formalin, veratridine and grayanotoxin (Gingras et al., 2014). A 
significant, though incomplete, reduction in pain behaviours elicited by intraplantar injection 
of the NaV1.7 activator OD1 was also observed in NaV1.7Advil conditional gene deletion mice, 
likely reflecting activity at NaV1.6 (Deuis et al., 2016). This raises questions as to whether or 
not NaV1.7 is crucial in all pathological pain states. Furthermore, there is limited information 
about pain other than that provoked by acute nociceptive stimuli in individuals with CIP due 
to the rarity of the condition. This information is also not available from the global NaV1.7 
knockout mice, as pathological pain states have not been systemically assessed (Gingras et 
al., 2014). However, this may take some time as raising these mice is a very slow and 
laborious task. 
 
Other types of pain have been assessed in the tissue-specific NaV1.7 conditional gene 
silencing mouse strains with mixed results. In inflammatory models, thermal allodynia is 
either attenuated or abolished in NaV1.7Nav1.8 transgenic animals, although mechanical 
allodynia remains unaffected (Nassar et al., 2004; Shields et al., 2012). In the spinal nerve 
transection (SNT) and chronic constriction injury (CCI) models of neuropathy, the pain-free 
phenotype was only evident in NaV1.7Wnt1 conditional gene silencing strains, consistent with a 
role of sympathetic sprouting in these models (Minett et al., 2014b; Minett et al., 2012; 
Nassar et al., 2004). However, peripheral neuropathy induced by the chemotherapeutic 
oxaliplatin was unaffected, indicating that some pathological pain states occur independently 
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of NaV1.7, with NaV1.6 being implicated (Deuis et al., 2013). In addition, lung cancer-
induced bone pain was also unaffected in NaV1.7Wnt1 conditional gene silencing animals, 
further demonstrating that pathological pain states can occur independently of NaV1.7.  
 
Indeed, at least one case of pathological pain in a patient with SCN9A loss-of-function has 
been described (Wheeler et al., 2014). Despite multiple painless fractures and injuries in early 
childhood, the patient reported troubling buzzing and vice-like squeezing sensations arising 
from nerve root compression that developed as a consequence of haematoma (Wheeler et al., 
2014). While the experience of pain is clearly a learned response, the patient nonetheless 
described these negative neuropathic symptoms in terms of unpleasant and distressing 
sensations consistent with the definition of pain. Additional cases of pain in patients with 
symptoms characteristic of channelopathy-associated congenital insensitivity to pain – 
although the genotype of these patients is unknown – have been described, including the 
presence of nephritic colic pains,  premenstrual syndrome symptomatology (Cesselin et al., 
1984) and abdominal discomfort due to parasitic worm infestation (Manfredi et al., 1981). 
These cases suggest that at least some types of pathological pain are likely to persist even in 
the absence of functional NaV1.7 channels, although additional studies are required to 
delineate which pathological pain states will most benefit from NaV1.7 inhibition as a 
therapeutic strategy. 
 
6. NaV1.7 as an analgesic target: Structural, functional and pharmacological 
evidence.  
The wealth of evidence supporting a crucial role for NaV1.7 in pain pathways has led to 
intense drug discovery efforts in the hope that subtype-selective NaV1.7 inhibitors would 
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constitute an analgesic panacea, effectively treating many, if not all, types of acute and 
chronic pain without serious side effects. However, the need for exquisite selectivity over 
other NaV isoforms has hampered progress in the area due to the high sequence similarity, 
particularly in the pore region of the channels (Table 5), where the binding sites of small 
molecule inhibitors including tetrodotoxins and the local anaesthetics are located. Notably, 
selectivity over NaV1.4 and NaV1.5 is required to avoid musculoskeletal and cardiac side 
effects, respectively, while activity at NaV1.6, a key isoform expressed at nodes of Ranvier in 
myelinated sensory and motor neurons, would likely be associated with paraesthesiae and 
paralysis. Similarly, inhibition of centrally expressed isoforms, including NaV1.1, NaV1.2 and 
NaV1.3, could lead to seizures or altered consciousness. While the level of subtype-selectivity 
required for safe use of NaV1.7 inhibitors is difficult to estimate, assuming equivalent tissue 
penetrance and on-target activity as well as a Hill slope of inhibition close to unity, a level of 
at least 100-fold selectivity would likely enable complete NaV1.7 inhibition in the absence of 
marked effects on the function of other isoforms. Greater subtype-selectivity likely would 
afford a greater safety margin and may be able to offset unfavourable pharmacokinetic 
properties. While use-dependence, or the ability to preferentially inhibit NaV channels in 
rapidly firing neurons, is a key property of non-selective inhibitors, arguably this property is 
less important for NaV1.7 because it is unlikely to contribute to rapid firing. However, use-
dependence likely imparts additional safety to compounds that lack a desirable level of 
subtype selectivity.  
 
6.1 NaV1.7 structure and pharmacology 
The amino acid sequence similarity of the nine human voltage-gated sodium channel α-
subunits NaV1.1 – NaV1.9 imply a common structural architecture (689 identical amino acids 
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(32%) between all nine sequences and 53% - 88% identity between any two isoforms; Table 
5).  
 
The α-subunits of NaV channels consist of a single polypeptide chain (1791 – 2016 amino 
acids long) that is folded into four homologous (but not identical) domains termed DI – DIV 
that are linked by three intracellular loops (L1-L3) (Figure 3). Each domain consists of six 
transmembrane segments (S1 – S6) with S1 – S4 in each domain comprising a voltage-
sensing domain (VSD), and S5 – S6 together with their extracellular linker (including the P-
loop) comprising the pore domain (PD) (Catterall, 2000; Guy and Seetharamulu, 1986; Noda 
et al., 1984). Thus, each α-subunit has four distinct VSDs and four PDs which assemble to 
form one sodium-selective pore. Sodium selectivity is achieved in the extracellular portion of 
the pore domain by tight association of the four P-loops that re-enter the membrane between 
the S5 and S6 segments in DI - DIV and includes several negatively charged residues 
(aspartic acid and glutamic acid) (Catterall, 2000). The intracellular loop L3 between DIII 
and DIV is important for channel inactivation (Stuhmer et al., 1989; Vassilev et al., 1989), 
especially the highly conserved residues IFM (West et al., 1992), which bind to the 
intracellular side of the pore domain and close the channel after activation.  
 
Voltage sensitivity is conferred by several highly conserved positive charges (arginine and 
lysine) in every third position of the S4 helices in each of the VSDs. Changes in the 
membrane potential causes movement of these “gating charges” across the cell membrane 
inducing a conformational change in the channel(Guy and Seetharamulu, 1986). In the resting 
state of neurons, the intracellular side is more negatively charged than the extracellular side. 
This inequilibrium produces a strong electric potential across the membrane, forcing the S4 
gating charges and thus all four VSDs towards the intracellular side of the membrane. 
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Activation of the channel following depolarizing voltage changes likely involves a “helical 
screw” or “sliding helix” mechanism in which S4 helices slide and rotate around their axes as 
they move toward the extracellular surface, changing channel conformation and allowing the 
pore domain to become permeable to sodium ions (Chanda and Bezanilla, 2002; Guy and 
Seetharamulu, 1986; Li et al., 2014; Stuhmer et al., 1989).  
 
Up to nine unique NaV channel binding sites have been proposed. It is, however, becoming 
increasingly clear that significant overlap likely occurs and that it will be necessary to revisit 
these definitions (Ahern et al., 2016). Broadly speaking, NaV modulators can be classified as 
pore blockers and gating modifiers, which in turn can be further refined according to their 
functional effects (Bagal et al., 2015). 
 
Pore blockers bind to the pore domain of NaVs, rendering the channels impermeable to Na+ 
ions. Peptide toxins like µ-conotoxins, but also the smaller neurotoxins tetrodotoxin (TTX) 
and saxitoxin (STX) bind to the extracellular side of the pore to occlude the opening, while 
small molecules such as local anaesthetics (e.g. lidocaine, benzocaine) bind to the 
transmembrane region inside the pore (Bagneris et al., 2014). As the pore domain (especially 
the P-loops and the transmembrane segments S5 and S6) is highly conserved between NaV 
isoforms (Table 6), compounds targeting this region are unlikely to display substantial NaV 
subtype selectivity. Notably, while tetrodotoxin and saxitoxin occlude the narrow part of the 
pore by binding to the selectivity filter in the P-loop, the binding site of pore blocker peptide 
toxins likely includes more than only the highly conserved P-loops (Hui et al., 2002; Korkosh 
et al., 2014). This may make it possible to find subtype selective pore blockers as the 
sequence alignment (Table 6) shows substantial sequence differences with respect to the 
whole S5-S6 linkers. 
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In contrast, gating modifiers associate with one or more of the VSDs and modulate 
conformational changes of the channel. The functional consequences of these interactions are 
varied and can include enhanced or reduced activation, enhanced or reduced fast inactivation, 
as well as less well-defined effects on slow inactivation and recovery from inactivation. 
While modification of NaV gating properties has been predominantly the purview of venom 
peptides and large toxins to date, the recently described aryl sulfonamide class of small 
molecule NaV inhibitors also acts through a voltage-sensor trapping mechanism. Importantly, 
the greater sequence divergence in the VSD domains, especially in the extracellular linkers, 
(Table 6) offers an opportunity for the development of highly subtype-selective NaV 
modulators. While the exact structure of mammalian NaV channels, as well as structural 
differences between isoforms, remains unknown, the recently described high-resolution 
crystal structures of homotetrameric bacterial voltage-gated sodium channels (Payandeh et 
al., 2011; Zhang et al., 2012) have provided significant insights. Nevertheless, the current 
models describing NaV channel function have hinted at multiple closed and inactivated states 
that may or may not be coupled. Modulators may trap any of these states or indeed modulate 
the coupling between these states (Karoly et al., 2010).  
 
Of note, while the NaV α-subunits form functional sodium channels if expressed alone 
(Goldin et al., 1986; Noda et al., 1986), they typically associate in vivo with cell type-specific 
auxiliary proteins, such as the β-subunits β1 – β4, to form multi-protein signalling complexes 
either through covalent or non-covalent interactions. The β-subunits modulate kinetics, 
voltage dependence and gating properties of the channel as well as expression and trafficking 
(Meadows and Isom, 2005; O'Malley and Isom, 2015). In addition, the β-subunits can 
substantially alter the kinetics and the extent of NaV inhibition by various modulators 
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(Gilchrist et al., 2013), adding additional complexity (that remains poorly understood) to the 
pharmacological requirements for developing selective NaV1.7 inhibitors. 
 
Finally, it has emerged that NaV channel function, and as a consequence likely NaV channel 
pharmacology, is also dependent on the composition of lipids in the cell membrane. NaVs can 
be present in lipid rafts, which are tightly packed lipid microenvironments enriched in 
cholesterol, sphingolipids and phospholipids with saturated acyl chains (Dart, 2010). In 
particular, lipid-dependent activity has been displayed in the bacterial channel homologues 
NaChBac, NavMs and NavSp (D'Avanzo et al., 2013). For each channel, there was greater 
activity in lipid compositions with zwitterionic phospholipids such as phospholipid 1-
pamitoyl 2-oleoyl phosphatidylethanolamine (POPE) and, more crucially, in conjunction with 
negatively-charged phospholipids such as phosphatidyl inositol (PI) or phosphatidyl glycerol 
(PG). Furthermore, the activity of these channels is sensitive to different negatively-charged 
lipids that are present (e.g. phosphatidylinositol (PI), phosphatidyl serine (PS), cardiolipin 
(CL) and phoshatidic acid (PA)). Phosphatidylinositol 4,5-bisphosphate (PIP2), a common 
modulator of various bacterial  NaVs, had no noticeable effect on NaChBac, but displayed 
inhibitory effects on NavMS and possibly activating effects on NavMs (D'Avanzo et al., 
2013).  
 
While prokaryote membranes commonly feature most of the lipids mentioned above, PI 
lipids are less common and PIP2 is mostly absent (Sohlenkamp et al., 2003), showing that 
these bacterial channels can be influenced by lipids typically not found in bacterial 
membranes. Lipid profiles may therefore have a role in regulating the physiological channel 
function for NaVs, and voltage-gated ion channels in general (Figure 3). This may be most 
prevalent for eukaryotic channels, where the variation of lipid profiles in different tissue, 
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such as muscle and central and peripheral nerves, may have a role in the regulation of 
function of the various isoforms of NaV channels. Lipid-enhanced channel activity may arise 
from either an effect on the local membrane fluidity or by direct interactions with the 
channel. Recent evidence shows that individual lipid molecules may specifically associate 
with membrane proteins, including NaVs (Ahuja et al., 2015; Gault et al., 2016). These 
interactions are still poorly characterized but are likely to be analogous to the structural role 
of water in protein and glycan folding and stability.  
 
A general challenge in accurately determining the kinetics of ligands that bind membrane 
proteins, such as NaV1.7, is to delineate direct interactions of the ligand with the channel 
from interactions with the lipid bilayer or individual components of the membrane leaflet 
(Klint et al., 2015; Sykes et al., 2014). For small molecules this can, in general, be corrected 
for by measuring partitioning coefficients (Sykes et al., 2014). Such assays are more difficult 
for peptides that demonstrated pH-dependent partitioning coefficients. For venom peptide 
modulators of NaV1.7, which contain highly cationic regions, the problem is exacerbated by 
non-specific binding to anionic membrane components such as ceramide-1-phosphate (CM-
p), PS and PG. Seemingly increased affinity of peptides that also show increased affinity 
against anionic membranes is therefore most likely due to an increase in the local peptide 
concentration at the membrane rather than direct influence of the anionic lipids on channel 
function.  
 
From the above it can be seen that channel function is characterised by a number of distinct 
closed, open and inactivated states that may or may not be coupled. The stability and 
coupling between these states can be modulated further by β-subunits, membrane 
composition, temperature and likely other factors such as pH and the presence or absence of 
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inflammatory mediators. The number of permutations highlights the challenges in accurately 
characterising modulators of NaV1.7, which may exert their effects by either stabilizing a 
particular state or modulating the coupling between any two states. Detailed characterization 
of modulators will therefore remain ambiguous until further structural data emerges linking 
the action of modulators to structurally distinct states.  
 
6.2 Selective NaV1.7 inhibitors 
One of the first described selective NaV1.7 inhibitors was ProTxII, a spider venom peptide 
isolated from the venom of the Peruvian green velvet tarantula Thrixopelma pruriens 
(Middleton et al., 2002; Schmalhofer et al., 2008) as part of drug discovery efforts by Merck. 
However, while ProTxII potently inhibits NaV1.7 in electrophysiological assays and is at least 
85–fold selective over all other isoforms assessed (Table 7), it failed to elicit analgesia after 
intravenous or intrathecal dosing in an inflammatory pain model (Schmalhofer et al., 2008). 
This lack of efficacy was attributed to its poor pharmacodynamic profile, in particular an 
extraordinarily slow on-rate and poor penetration into the perineurium. However, given that 
axonal conduction is unlikely to be a key site of action for Nav1.7 inhibitors, other 
mechanisms likely contribute to the lack of analgesia. Notably, complete inhibition of NaV1.7 
in the absence of effects at other isoforms could not be achieved at any concentration, and 
accordingly, higher systemic or intrathecal doses of ProTxII were lethal (Schmalhofer et al., 
2008).  
 
Interestingly, the high selectivity of ProTxII for NaV1.7 involved a key residue close to the 
extracellular loop of S3 in domain II, F813, which is replaced by a serine residue in hNaV1.6 
and a glycine residue in all other tested isoforms (Schmalhofer et al., 2008). A motif 
containing this same unique Phe residue (VELFLADVEG) was later used to generate a 
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monoclonal blocking antibody (SvMab1) with high selectivity for NaV1.7 (Lee et al., 2014). 
Consistent with this antibody targeting the same binding site as ProTxII, the selectivity 
profile of SvMab1 across other NaV isoforms was similar (Table 7), albeit only partial 
inhibition could be achieved (Lee et al., 2014). Notably, although the S3-S4 extracellular 
loop of domain II targeted by SvMab1 has low sequence similarity particularly in NaV1.5 and 
NaV1.8, the activity at these isoforms was very similar to that of more closely related 
isoforms such as NaV1.1 and NaV1.6, suggesting that SvMab1 interacts with several 
additional conserved extracellular residues. Although SvMab1 is proteinaceous in nature 
(MW 167 kDa) and could be expected to exhibit similar on-rate and tissue penetration issues 
as ProTxII, analgesia – albeit surprisingly short-lived for a monoclonal antibody – was 
reported in the formalin and chronic constriction injury models after intrathecal, intraplantar 
and intravenous administration. Unfortunately, due to limitations in SvMab1 supply, this 
activity has not yet been replicated. Another, initially promising, highly selective venom-
derived NaV1.7 inhibitor was isolated from the Chinese red-headed centipede S. subspinipes 
mutilans and demonstrated effective analgesia in multiple pain models, as did typically sub-
therapeutic doses of morphine 122. However, the identity of the active molecule and whether it 
targets NaV1.7 remains unclear, as neither synthetic nor recombinant µ-SLPTX-Ssm6a 
possessed in vitro activity consistent with NaV1.7 inhibition (Murray et al., 2015; Yang et al., 
2013)  
 
Nonetheless, venom-derived peptides continue to provide key leads for the development of 
subtype-selective NaV1.7 inhibitors owing to their potency, selectivity, and metabolic 
stability as well as the ease with which structure-activity studies based on alanine-scans can 
be carried out. Using this approach, the selectivity of the tarantula peptide GpTx-1 for NaV1.7 
over NaV1.4 and NaV1.5 was improved to 318 and 9937-fold, respectively, by replacing an 
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arginine in position 18 with a lysine residue.(Murray et al., 2015; Murray et al., 2016) 
Similarly, potency of huwentoxin-IV (µ-theraphotoxin-Hs2a or HwTx-IV) for NaV1.7 was 
increased 42-fold in the triple mutant E1G,E4G,Y33W-HwTx-IV (Revell et al., 2013). 
Unfortunately, while a plethora of peptides from venomous animals with at times exquisite 
potency at NaV1.7 have been reported, full subtype-selectivity across all NaV isoforms, 
including the key TTX-sensitive off-targets NaV1.1 and NaV1.6, is rarely available (Table 7). 
This lack of systematic study, in combination with the lack of reproducibility of some studies, 
and the possibly mismatched routes of administration, makes it very difficult to assess the 
validity claims that “NaV1.7 selective” molecules are analgesic due to on-target activity. 
 
The difficulties described above aside, the extraordinary subtype selectivity of the molecules 
ProTxII and SVMab1 illustrates a key point: given the high sequence homology between NaV 
isoforms in the pore region, the level of selectivity required for therapeutic targeting of 
NaV1.7 is more likely to be achieved by targeting the more divergent voltage-sensing 
domains (Figure 3). This approach has led to the development of highly subtype-selective 
small molecules including PF-04856264, PF-05089771 and GX-674, which bind to residues 
in S2 (Y1537 and W1538) and S3 (D1586) in domain IV to achieve selectivity for NaV1.7 
(Ahuja et al., 2015; McCormack et al., 2013). 
Consistent with an interaction site located in a region of the channel intimately involved with 
inactivation, PF-04856264 binds preferentially to the slow-inactivated state (McCormack et 
al., 2013). Elegant structural studies have confirmed that NaV1.7-selective aryl sulfonamides 
bind with high affinity to the non-resting state conformation of the domain IV voltage sensor 
via the fourth gating charge residue, locking it into a nonconductive state and thus preventing 
recovery from inactivation (Ahuja et al., 2015).  Accordingly, PF-04856264 inhibits NaV1.7 
with an IC50 of 28 nM after a depolarizing pre-pulse that favours movement of the channel 
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equilibrium towards the slow-inactivated state, while almost no inhibition was apparent even 
at 1 µM after depolarization from the resting state (McCormack et al., 2013). 
 
A compound related to PF-04856264, called PF-05089771, was entered in clinical trials 
where, after initial promising results in postoperative dental pain, it was advanced to 
treatment of erythromelalgia and painful diabetic neuropathy (Alexandrou et al., 2016). 
However, despite on-target activity of PF-05153462 (another related aryl sulfonamide with 
improved selectivity over NaV1.6) in stem cell-derived sensory neurons from patients with 
the erythromelalgia gain-of-function mutations S241T, I848T, V400M or F1449V, the 
analgesic effect of PF-05089771 in a cross-over placebo-controlled trial assessing analgesic 
efficacy after a single oral dose was rather modest. Compared with placebo, statistical 
significance for PF-05089771 was only achieved at the 4 hour post-dosing time-point, 
although peak plasma levels exceeded the in vitro IC50 by a factor of approximately 10-fold, 
and pain scores were essentially unchanged in 3/5 probands (Cao et al., 2016).  
 
This lack of broadly effective analgesia is somewhat surprising, given that more than 80% of 
the TTX-sensitive Na+ current in small dorsal root ganglion neurons giving rise to 
unmyelinated nociceptors was inhibited by PF-05198007, another NaV1.7 inhibiting 
trifluoromethyl substituted aryl sulfonamide analogue with slightly improved selectivity over 
NaV1.1 and NaV1.6 (Alexandrou et al., 2016). PF-05198007 also significantly decreased 
dorsal root ganglion neuron excitability at NaV1.7-selective concentrations, with an 
approximately 40% increase in current required to elicit action potential firing. This 
observation confirms an important role in setting the action potential threshold in small dorsal 
root ganglion neurons (Alexandrou et al., 2016). In addition, consistent with the previously 
discussed putative role for NaV1.7 in spinal neurotransmitter release, excitatory postsynaptic 
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potentials were virtually abolished by PF-05198007 applied either spinally or at the dorsal 
roots (Alexandrou et al., 2016). Perhaps due to these results, clinical trials assessing efficacy 
of PF-05089771 in chronic neuropathic pain no longer appear on the clinical trials pipeline of 
Pfizer as of May 2016 .  
 
A clear gap in efforts to translate the excellent in vitro selectivity and potency of aryl 
sulfonamides to the clinic is the broad lack of analgesic efficacy in relevant animal models. 
PF-04856264 was analgesic in a model of pain based on intraplantar injection of a NaV1.7 
activator at a dose of 30 mg/kg, but not in formalin- or carrageenan-induced pain at the same 
dose (Deuis et al., 2014).  Notably, in vivo efficacy of PF-04856264, PF-05089771, PF-
05153462 or PF-05198007 has not been reported in any other animal model of pain, 
suggesting that preference for the slow-inactivated state may not translate to significant 
analgesic or antinociceptive effects. Indeed, slow inactivation is enhanced in several 
mutations associated with IEM (Table 3), suggesting that there is no clear functional 
association of the slow inactivated state with pain. 
 
Notably, an aryl sulfonamide (Cpd 3) that showed efficacy in rodent models of formalin-
induced pain and Complete Freund’s adjuvant-induced cold allodynia at doses exceeding 30 
mg/kg (Focken et al., 2016) has – like PF-05089771 – limited selectivity over NaV1.6 and 
NaV1.2. Given clear evidence that non-selective NaV inhibitors are undoubtedly highly 
effective analgesics, and that state-dependent blockers can have excellent safety profiles, 
evidence that selective NaV1.7 inhibitors will provide effective analgesia is thus inconsistent 
at the moment.  
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Alternatively, although the pharmacokinetic parameters of PF-05089771 appear generally 
promising, including good oral bioavailability leading to relevant plasma levels (Cao et al., 
2016), insufficient central nervous system exposure – suggested by the poor blood-brain 
barrier permeability of other aryl sulfonamides (Focken et al., 2016)– may limit effects on 
spinal neurotransmitter release and hence limit analgesic efficacy. Accordingly, although 
non-selective for NaV1.7, the state-dependent NaV inhibitor CNV1014802 is able to cross the 
blood-brain barrier and, like several other use-dependent NaV inhibitors, appears to be 
analgesic in certain types of pain, including trigeminal neuralgia .  
 
A myriad of additional small molecule NaV1.7 inhibitors with unknown selectivity have been 
described (Sun et al., 2014a). While some of these, including TV-45070 (Xen407), have been 
advanced to clinical trials and have shown some efficacy (Goldberg et al., 2012), in light of 
clear contributions of NaV1.1 (Osteen et al., 2016), NaV1.3, NaV1.6 (Deuis et al., 2013), 
NaV1.8 (Han et al., 2016) and NaV1.9 (Dib-Hajj et al., 2015) to pain, analgesic effects of 
compounds with poor or unreported subtype selectivity over these isoforms need to be 
viewed with caution. Accordingly, only sufficiently subtype selective inhibitors will provide 
insight into whether NaV1.7 inhibitors will be effective analgesics.  
 
6.3 NaV1.7 as an analgesic target – what is the evidence beyond genetics? 
The genetic evidence supporting a crucial role for NaV1.7 in pain pathways is without doubt 
compelling. However, several key questions remain to be addressed before translation of 
highly selective NaV1.7 inhibitors as effective analgesics to the clinic can be achieved. These 
include fundamental questions about where in nociceptive pathways NaV1.7 needs to be 
inhibited, what level of functional inhibition is required to effect analgesia, and which, if any, 
pathological pain conditions will respond favourably to highly selective NaV1.7 inhibitors. 
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It is clear that enhanced NaV1.7 activity – whether as a result of pharmacological modulation 
by selective toxins (Deuis et al., 2016) or gain-of-function mutations – is associated with 
enhanced nociception and pain. Intriguingly, the molecular basis for differences in the 
anatomical location of pain in IEM and PEPD, as well as the age of disease onset, remain 
unclear. While the age of symptom onset has been correlated with the degree of shift in 
voltage-dependence of activation resulting from the mutation (Cheng et al., 2008; Han et al., 
2009), it is unclear why smaller shifts would only become noticeable in the second decade of 
life. In addition, significant variability in onset can be observed even in patients with the 
same mutation. It is plausible that alternate splicing, including tissue-specific splicing, or age-
related changes in NaV1.7, may contribute to the distinct phenotypic presentation.  
 
Of note, while heterozygosity is sufficient to achieve a functional phenotype in IEM and 
PEPD, substantial loss of functional NaV1.7 channels is required to achieve a painless 
phenotype. While the exact level remains to be determined, given that most CIP cases 
described to-date are homozygous mutations leading to complete loss of functional NaV1.7, it 
seems likely that inhibition, or loss, of substantially greater than 50%, possibly approaching 
100%, of functional channels is required to achieve measurable  analgesia. Consistent with 
this notion, no polymorphisms associated with decreased pain sensitivity due to diminished, 
but not abolished, function of NaV1.7, have been reported to-date. Accordingly, the question 
arises whether graded analgesia afforded by pharmacological inhibition of NaV1.7 can be 
achieved at all. The clinical implications of pharmacologically induced insensitivity to pain 
are serious, and may limit use of selective NaV1.7 inhibitors from a universal panacea for all 
pathological pain to restricted applications in in-patient care where close supervision to avoid 
unintended painless injury is possible.  
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In addition to the challenge of determining the level of pharmacological NaV1.7 inhibition 
that is required for analgesic effects, it is also unclear where in the pain pathway NaV1.7 
needs to be blocked, and for how long. The lack of broad analgesic efficacy of selective 
NaV1.7 inhibitors such as the recently described aryl sulfonamides suggests that inhibition of 
NaV1.7 at peripheral free nerve endings is not sufficient to block the generation of pain – 
albeit activation of NaV1.7 at nerve endings is clearly able to elicit pain. Given that the 
biophysical properties of NaV1.7 make it unlikely that it contributes substantially to 
sustained, rapid action potential firing along axons, a key role in spinal neurotransmitter 
release seems plausible. Indeed, dorsal root stimulation in CIP patients elicited paraesthesias 
and cortical potentials, but not pain (Manfredi et al., 1981), suggesting that spinal effects are 
important even if abnormal signal transformation and transduction contribute to the painless 
phenotype. However, even intrathecal delivery of the highly selective NaV1.7 inhibitor 
ProTxII did not result in analgesia (Schmalhofer et al., 2008), highlighting the complex role 
of NaV1.7 in nociceptive pathways. While contribution of non-sensory neurons to painless 
phenotypes was revealed in pivotal knockout studies (Minett et al., 2014b; Minett et al., 
2012), in both humans with CIP as well as relevant transgenic mouse models, NaV1.7 is lost 
in utero. Although developmental effects can be largely ruled out since inducible NaV1.7 
knockout also leads to analgesia, it is intriguing to note that this effect developed rather 
slowly over many days (Minett et al., 2014b). It is unclear whether this delay represents slow 
turnover of NaV1.7 at the protein level, or hints at more complex mechanisms leading to loss 
of pain: given that upregulation of endogenous opioids appears to be causally linked to CIP, 
perhaps only long-term or sustained pharmacological inhibition of NaV1.7 will lead to 
antinociception. Notably, all studies reported to date have assessed analgesic efficacy after 
acute dosing, and in vivo effects of continued NaV1.7 block remain to be determined. The 
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promise of universally effective analgesia provided by selective NaV1.7 inhibitor is in 
addition drawn into question by observations that not all types of pathological pain are absent 
in humans and mice lacking functional NaV1.7.   
 
Additional roles of NaV1.7 in the physiology of olfaction and feeding behaviour are 
beginning to emerge. While deletion of NaV1.7 in AGRP neurons specifically led to slight 
decrease in body weight, deletion of NaV1.7 in POMC and PVH neurons led to significant 
weight gain (Branco et al., 2016). Interestingly, it is unclear how this relates to the observed 
effects of global NaV1.7 knockout on food-seeking behaviour and feeding. The postnatal 
lethality of global NaV1.7 KO pups was initially attributed to failure to smell (Minett et al., 
2012; Nassar et al., 2004); however, selective loss of NaV1.7 in olfactory neurons led only to 
reduced feeding but not post-natal lethality (Weiss et al., 2011). While it is possible that loss 
of NaV1.7 was incomplete in NaV1.7Osm conditional knockout mice, postsynaptic transmission 
from olfactory sensory neurons was completely absent and animals were unable to detect a 
variety of odors (Weiss et al., 2011). It is thus plausible that in addition to a loss of smell, a 
loss of central NaV1.7, either alone or in combination with altered afferent input, contributes 
to the absence of food seeking behaviour, and thus lethality in rodents. Consistent with very 
low expression in human CNS, no clear effects on body weight have been described in 
humans with loss or gain-of-function mutations to-date. In addition, given that deletion of 
NaV1.7 in subtypes of hypothalamic neurons has opposing effects on appetite, the overall 
effect of pharmacological inhibition on body weight remains to be determined. 
 
Despite, or because of, these emerging complexities, NaV1.7 remains one of the most 
attractive pain targets to-date. Despite the significant advances that have been made, several 
key questions remain, including the mechanisms underlying the intriguing relationship of 
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gain-of-function mutations with thermal and mechanical stimuli, and systematic evaluation of 
the contribution of endogenous opioids to congenital insensitivity to pain. While some of 
these unknowns – including the types of pathological pain likely to be susceptible to 
pharmacological inhibition of NaV1.7 and the degree of NaV1.7 inhibition required to cause 
analgesia – can be addressed using existing genetic approaches and animal models, others 
will require the discovery or design of additional, highly subtype-selective NaV1.7 inhibitors. 
These include compounds that block multiple states of NaV1.7 including the resting and (fast) 
inactivated state, compounds that can achieve full channel inhibition irrespective of 
membrane potential, and compounds that are able to penetrate both the perineurium and 
spinal sites after systemic administration. Synergistic effects of selective NaV1.7 inhibitors, 
both with opioids, NaV1.8 or NaV1.9 inhibitors, or NaV1.7 inhibitors with complementary 
mechanism of action, remain to be determined and will provide important information on the 
clinical potential and application of NaV1.7 inhibitors. Insights from the first sodium channel 
crystal structures have already contributed to the development of novel subtype-selective 
inhibitors, and detailed structural information on additional states of the channel will 
undoubtedly provide important information that will enable translation of the remarkable 
genetic evidence supporting the unique role of NaV1.7 in pain to novel treatment approaches 
for pain. 
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Figure 1. Expression profile of NaV1.7. a) In the rodent central nervous system, NaV1.7 is 
expressed in the pituitary gland, subfornical organ as well as several hypothalamic nuclei 
(Ahmad et al., 2007; Morinville et al., 2007). In the arcuate nucleus (ARC), dorsomedial 
nucleus (DMH) and paraventricular nucleus (PVH), NaV1.7 is expressed in Agrp, Npy and 
POMC-expressing neurons where it contributes a persistent current that is crucial for synaptic 
integration. Note that NaV1.7 expression in these brain regions is substantially lower in 
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primates and humans b) NaV1.7 is expressed along the olfactory sensory nerve from the 
olfactory epithelium to the branches of the olfactory nerve but absent in mitral and granule 
neurons receiving synaptic inputs from olfactory sensory neurons. In these neurons, NaV1.7 is 
crucial for neurotransmitter release and absence of functional NaV1.7 leads to anosmia. c) In 
sensory neurons, NaV1.7 is expressed in dorsal root ganglion neuron cell bodies, along axons, 
in the central terminals as well as in d) peripheral nerve terminals.  MPO, medial preoptic 
nucleus; PVH, paraventricular nucleus; SO, supraoptic nucleus; AHT, anterior hypothalamic 
nucleus; VMH, ventromedial nucleus; MMB, mammillary body; ARC, arcuate nucleus; 
DMH, dorsomedial nucleus; Agrp, Agouti-related peptide neurons; Npy, Neuropeptide Y 
neurons; POMC, pro-opiomelanocortin neurons. 
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Figure 2. Mutations associated with NaV1.7-mediated genetic conditions. The schematic 
illustration of the NaV1.7 channel α-subunit secondary structure highlights the locations of 
gain-of-function mutations causing NaV1.7 related pain disorders: erythromelalgia (IEM; red 
symbols), small-fibre neuropathy (SFN; green symbols), paroxysmal extreme pain disorder 
(PEPD; yellow symbols) and Distal Limb Pain (turquoise symbol). A mutation in position 
228 was reported in IEM and SFN patients (dark blue symbol) and a mutation in position 
1632 was observed in IEM and PEPD cases (purple symbol). The VSDs are depicted in blue 
and the pore domains in pink. The secondary structure of the Nav1.7 channel was designed 
using the CorelDraw Graphics Suite X7 software. The human SCN9A amino acid sequence 
isoform 3 was obtained from Uniprot database (Uniprot query: Q15858). 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
75 
 
 
Figure 3. Architecture of voltage-gated sodium channels. a) Top view of the channel in 
cartoon representation. The channel consist of four homologous domains (DI-DIV) (colour 
coded). Each domain has a segment that forms a voltage sensing domain (VSD) and a 
segment that forms part of the pore domain (PD). The VSD from one domain makes contacts 
with the pore segment of the adjacent domain. b) Side view of the channel in surface 
representation (colour coding same as in panel a). The membrane embedded section of the 
channel contains a hydrophobic cavity which provides access to the channel pore for many 
local anaesthetics. c) Top view of the channel highlighting the selectivity filter. The pore 
segments contain a P-loop which folds over the channel cavity and provides sodium 
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selectivity. It is also the binding site of several toxins. d) View of the VSD central cavity in 
cartoon representation. This is also the binding site aryl sulfonamides (stick representation) 
that stabilise the inactivated state of the channel. The structure also shows the stable binding 
of lipids (sphere representation) in the cavity formed between the VSD helices. Structures are 
based on (Payandeh et al., 2011) 
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Table 1. Hereditary sensory neuropathies characterised by absence of pain sensation. Mutations in SCN9A underlie HSAN2d and 
channelopathy-associated congenital insensitivity to pain (CIP) (OMIM 243000). HSAN (hereditary sensory and autonomic neuropathy); HSN 
(hereditary sensory neuropathy). Table modified from (Rotthier et al., 2012) and based on information from OMIM (Online Mendelian 
Inheritance in Man). 
Type/Classification Inheritance Gene/locus Protein Clinical presentation Age at 
onset 
OMIM Reference 
HSAN1a  
(HSAN-Ia) 
Autosomal 
dominant 
SPTLC1/9q22.31 Serine palmitoyltransferase long-
chain base subunit 1 
Hereditary perforating ulcers, 
distal sensory loss to sharp, hot, 
and cold sensation, deafness, 
mutilating acropathy, lancinating 
pain 
Childhood 
to 
adulthood 
162400 (Penno et 
al., 2010) 
HSAN1b 
(HSAN-Ib) 
Autosomal 
dominant 
3p24-p22 unknown Chronic cough/syncope, impaired 
laryngeal sensation, 
gastroesophageal reflux, sensory 
loss, hyporeflexia 
adulthood 608088 (Spring et 
al., 2005) 
HSAN1c  
(HSAN-Ic) 
Autosomal 
dominant 
SPTLC2/14q24 Serine palmitoyltransferase long-
chain base subunit 2 
Panmodal sensory loss, 
ulcerations, osteomyelitis, 
dysesthesias 
Childhood 
to 
adulthood 
613640 (Rotthier et 
al., 2010) 
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HSAN1d  
(HSAN-Id) 
Autosomal 
dominant 
ATL1/ 14q22.1 Altlastin 1 Panmodal distal sensory 
neuropathy, ulceration, 
hyporeflexia 
adulthood 613708 (Guelly et 
al., 2011) 
HSAN1e  
(HSAN-Ie) 
 
Autosomal 
dominant 
DNMT1/ 19p13.2 DNA methyltransferase 1 Panmodal sensory neuropathy, 
ulcerations and amputations, 
progressive deafness and early-
onset dementia 
adulthood 614116 (Klein et al., 
2011; Sun et 
al., 2014b) 
HSAN1f  
(HSAN-If) 
Autosomal 
dominant 
ATL3/ 11q13.1 Altlastin 3 Painless ulceration of lower limbs, 
amputations, osteomyelitis,  
adulthood 615632 (Kornak et 
al., 2014) 
HSAN2a 
(HSAN-IIa) 
Autosomal 
recessive 
WNK1/HSN2/12p13.33 HSN2 Cold-induced distal paraesthesias, 
anaesthesia, loss of 
mechanosensation, distal 
mutilation, acropathy, 
osteomyelitis 
childhood 201300 (Lafreniere 
et al., 2004; 
Riviere et 
al., 2004) 
HSAN2b 
(HSAN-IIb) 
Autosomal 
recessive 
FAM134B/ 5p15.1 Fam134b Impaired nociception, progressive 
mutilating distal ulcerations, 
hyperhidrosis, urinary 
incontinence 
Childhood 
to 
adulthood 
613115 (Khaminets 
et al., 2015; 
Kurth et al., 
2009) 
HSN2c Autosomal KIF1A/ 2q37.3 Kinesin family member 1A progressive distal sensory loss Childhood 614213 (Riviere et 
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(HSN-IIc) recessive leading to ulcerations and 
amputations, distal muscle 
weakness 
al., 2011) 
HSAN2d  
(HSAN-IId) 
Autosomal 
recessive 
SCN9A/ 2q24.3 NaV1.7 Hyposmia, progressive distal 
anaesthesia, lack of 
thermosensation, hyporeflexia, 
hypohidrosis, hearing loss 
 
 
Childhood 
to 
adulthood 
243000 (Yuan et al., 
2013) 
HSAN3 
(HSAN-III) 
Autosomal 
recessive 
IKBKAP/9q31.3 Inhibitor of kappa light 
polypeptide gene enhancer in B 
cells, kinase complex-associated 
protein 
Alacrima, absence of lingual 
fungiform papillae with impaired 
taste, vasomotor instability, 
hypoactive or absent deep tendon 
reflexes, relative indifference to 
pain and temperature. 
congenital 223900 (Lee et al., 
2009; Riley 
et al., 1949) 
HSAN4  
(HSAN-IV) 
Autosomal 
recessive 
NTRK1/1q23.1 Tropomyosin receptor kinase A Absence of nociception and 
thermosensation, self-mutilation, 
anhidrosis, developmental delay 
congenital 256800 (Dyck et al., 
1983; Dyck 
and Ohta, 
1975; 
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Shatzky et 
al., 2000) 
HSAN5  
(HSAN-V) 
autosomal 
recessive 
NGF/1p13.2 Nerve growth factor Selective loss of nociception and 
thermosensation affecting the 
extremities 
congenital 608654 (Dyck et al., 
1983) 
HSAN6 
(HSAN-VI) 
autosomal 
recessive 
DST/6p12.1 dystonin neonatal hypotonia, respiratory 
and feeding difficulties, lack of 
psychomotor development, 
autonomic abnormalities, 
areflexia, absent axonal flare 
response 
congenital 614653 (Edvardson 
et al., 2012) 
HSAN7 
(HSAN-VII) 
De novo 
dominant 
SCN11A/3p22.2 NaV1.9 self-mutilations, slow-healing 
wounds, multiple painless 
fractures, mild muscle weakness, 
delayed motor development, 
reduced motor and sensory nerve 
conduction velocities with normal 
amplitudes, no sensory axonal 
loss, hyperhidrosis,  
congenital 615548 (Leipold et 
al., 2013; 
Woods et 
al., 2015) 
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gastrointestinal dysfunction 
HSAN8 
(HSAN-VIII) 
autosomal 
recessive 
PRDM12/ 9q34.12 PRDM12 Loss of nociceptors and 
thermosensors. Reduced sweating 
and tearing 
congenital 616488 (Chen et al., 
2015) 
HSAN9 
(HSAN-IX) 
autosomal 
recessive 
CLTCL1 CHC22 No nociception or 
mechanosensation; learning 
difficulties 
congenital n/a (Nahorski et 
al., 2015) 
Channelopathy-
associated 
insensitivity to 
pain; Congenital 
autosomal 
recessive 
indifference to 
pain; Congenital 
Insensitivity to 
Pain (CIP) 
autosomal 
recessive 
SCN9A/ 2q24.3 NaV1.7 No nociception, anosmia, normal 
mechanosensation and 
thermosensation 
 
congenital 243000 
 
(Cox et al., 
2006) 
Congenital 
insensitivity to 
   No nociception, absent cutaneous 
innervation, normal vascular and 
  (Bowsher et 
al., 2009) 
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Pain with 
hyperhidrosis 
sweat gland innervation, 
hyperhidrosis 
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Table 2. Congenital Insensitivity to Pain associated with NaV1.7 loss-of-function mutations. 
A: absent; P: present; N: normal; ↓: decreased; CIP: congenital insensitivity to pain; CIPA: congenital insensitivity to pain with anhidrosis; 
HSAN2d: hereditary sensory and autonomic neuropathy type 2 d 
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c.774_775
delGT; 
c.2488C>
T 
Frameshift; stop 
codon p. R830X 
Non-
functional 
protein 
CIP A                 A         (Nilsen et al., 2009; Weiss et al., 2011) 
c.828delG
T; 
c.2575C>
T 
Frameshift; stop 
codon DI/DII 
Non-
functional 
protein 
CIP A P N N N N N ? ↓ A  ↓    N N A    N ↓ A   (Nilsen et al., 2009) 
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c.829C>T 
 
Stop codon 
p.R277X 
Non-
functional 
protein 
CIP A P N  N  N  N A  N N N   N A N   N  A   (Goldberg et al., 2007) 
c.901ins5
G>C; 
c.5323T>
A 
Misplicing; 
p.W1775R 
missense 
mRNA 
decay; 
~70% 
reduction in 
peak current 
CIP A P              N  A         (Emery et al., 2015) 
c.966-
2A>G; 
c.1567C>
T 
 
Splice junction 
mutation 
p.R523>X, 
p.K655>R 
mRNA absent CIP A P        A            N N    (Klein et al., 2013) 
c.984C>A 
 
Stop codon 
Y328X 
Non-
functional 
protein 
CIP A
/↓ 
P N  N N N  N A   N N N N N  N   N  A  N (Ahmad et al., 2007; Goldberg et al., 
2007) 
c.1126 
A>C; 
c.1124del
Frameshift; stop 
codon DIS6 
Non-
functional 
protein 
CIP A P N N  N N  N   ↓ N  N   A N N N N N    (Shorer et al., 2014) 
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G 
c.1376C>
G 
Stop codon 
p.S459X 
Non-
functional 
protein 
CIP A P N  N  N  N   N N  N N   N N N N N A  N (Cox et al., 2006) 
c.1567C>
T 
Stop codon  
p. R523X 
Non-
functional 
protein 
CIP A P     N  N    N  N N  N      A  N (Kurban et al., 2010) 
c.2076_20
77insT; 
c.4366-
7_10delG
TTT 
 
Stop codon 
p.E693X; 
Splice junction 
mutation (major 
allele) 
Non-
functional 
protein; none 
(major allele) 
CIP A P N  N N N  N A  N N N   N A N   N  A   (Goldberg et al., 2007; Klein et al., 
2013) 
c. 
2298delT 
Stop codon 
p.I767X 
Non-
functional 
protein 
CIP A P N  N  N  N   N N  N N   N N N N N A  N (Cox et al., 2006) 
c.2488C>
T 
 
Stop codon 
p.R830X 
Non-
functional 
protein 
CIP A P N  N  N  N A   N N   N A N     A   (Goldberg et al., 2007) 
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c.2488C>
T;  
c.5318del
A 
Stop codon p. 
R830X; 
Frameshift 
Non-
functional 
protein 
CIP A P     ↓ A ↓ A  N N N N  N A     ↓    (Ramirez et al., 2014) 
c.2687G>
A 
Missense 
p.R896Q 
Loss of 
function, 
decreased 
membrane 
trafficking/po
re misfolding 
CIP A P N   N      ↓ N    N  N    ↓    (Cox et al., 2010) 
c. 
2691G>A 
Stop codon  
p.W897X 
(DIIS5/S6) 
Non-
functional 
protein 
CIP A P N  N  N  N   N N  N N   N N N   A  N (Cox et al., 2006) 
c.2691G>
A; 
c.5173G>
C 
Stop codon 
p.W897X  
(DIIS5/S6) 
 
Non-
functional 
protein 
CIP A P N      ↓ A  P N N N  N A    N     (Bogdanova-Mihaylova et al., 2015) 
 Stop codon 
p.E970X  
Non-
functional 
CIP
A 
A P ↓         N N    A  N        (Bartholomew et al., 2014) 
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protein 
c.2755T>
G 
Stop codon 
DIIS5/S6 
Non-
functional 
protein 
CIP A P     N A N A  ↓ ↓ ↓ ↓  ↓ A     A    (Peddareddygari et al., 2014) 
c.3600del
T 
 
Framshift 
truncation 
p.F1200LfsX33 
Non-
functional 
protein 
CIP A P N  N N N  N A  N N N   N A N     A   (Goldberg et al., 2007) 
c.3703_37
13del; 
c.4975A>
T 
 
Frameshift 
p.I1235 leufsX2; 
Stop codon 
K1659X 
Non-
functional 
protein 
CIP A P N  N  N  N A  N N N   N A N   N  A   (Goldberg et al., 2007) 
c.3707C>
A; 
c.5492T>
G 
p.A1236E 
missense;  
stop codon p. 
L1831X 
~90% 
reduction in 
peak current; 
~70% 
reduction in 
peak current 
CIP A P        A      N  A         (Emery et al., 2015) 
c.4975A> Stop codon p. Non- CIP A                 A         (Weiss et al., 2011) 
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T; 
c.3703del
ATAGCA
TATGG 
K1659X; 
frameshift 
functional 
protein 
c.3993del
GinsTT 
Stop codon 
DIIIS5 
Non-
functional 
protein 
HSA
N2d 
↓/
A 
P ↓    A A A A  ↓ N N N N    ↓ N ↓     (Yuan et al., 2013) 
c.4108_41
22del15; 
c.4477del
A 
 
In-frame 
deletion 
∆R1370_L1374 
; truncating 
mutation 
I1493SfsX8 
Loss of 
function, 
decreased 
membrane 
trafficking/po
re misfolding 
CIP A P N N N N N  N   N
/↓ 
N          ↓/
A 
   (Cox et al., 2010) 
c.4462C>
T 
 
Stop codon 
p.R1488X 
Non-
functional 
protein 
CIP A P N  N  N  N A  N N N   N  N   N  A   (Goldberg et al., 2007) 
c.4795C>
T 
Stop codon 
p.R1599X 
Non-
functional 
protein 
CIP A P N   N      N N  N   A         (Mansouri et al., 2014) 
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c.5067G>
A 
 
Stop codon 
p.W1689X 
Non-
functional 
protein 
CIP A P N  N  N  N A  N N N   N A N     A   (Goldberg et al., 2007) 
c.5155 
T>C; 
c.3467+3 
delA 
p. C1719R; 
splice mutation  
unclear CIP ↓ P  N N  ↓ A N A  N N  N N N A N N N ↓ N   N (Staud et al., 2011) 
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Table 3. Painful conditions associated with NaV1.7 gain-of-function mutations. Definitions: Temperature: temperature at which in vitro 
characterization was carried out (in °C); ∆ V50 activation (mV): change in voltage-dependence of channel activation relative to wild-type control 
in mV; ∆ V50 inactivation (fast): change in voltage-dependence of fast channel inactivation relative to wild-type control in mV; ∆ V50 
inactivation (slow): change in voltage-dependence of slow channel inactivation relative to wild-type control in mV; Slow inactivation: effect on 
slow inactivation but quantification of change in voltage-dependence is not available. Abbreviations and symbols: ↓ - decreased/attenuated; ↑ - 
increased; ↔ - normal/unchanged; P – Partial; Y – Yes; U- unchanged; RT- room temperature; AH – generalised anhydrosis; AVD- Adrenergic 
vasomotor dysfunction; E- extremities (feet, hands); R- rectal; O-oral; Nr: not reported. Colour code:  inherited erythromelalgia (IEM; red 
symbols), small-fibre neuropathy (SFN; green symbols), paroxysmal extreme pain disorder (PEPD; yellow symbols), Distal Limb Pain 
(turquoise symbol). Both IEM and SFN symptoms (dark blue symbol); both IEM and PEPD symptoms (purple symbol). 
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IEM A29G Q10R RT -5.3 ↓ ↑ ↔ ↔   -4.8   ↔  ↔ E  ?  14 Exercise, warmth (Han et al., 
2009) 
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IEM  Q10K               E  Y  35 Standing, exercise, heat, (Klein et al., 
2013) 
 
IEM A406G I136V RT -5.7/-9.4 ↔ ↑ ↔/+3.7 ↑ ↑  -8 ↑  ↑   E  Y  9-22 exercise, heat, footwear (Cheng et al., 
2008; Lee et 
al., 2007; Wu 
et al., 2013) 
 
35 -9.7   +7.3    +15.1      
SFN G554A R185H 21 ↔  ↔ ↔    ↔  ↔ 
↑ 
↑  ↔ E OH, dry 
mouth, 
constipation, 
palpitations 
Y/
N 
 14-
64 
Exercise, alcohol, 
warmth, cold 
(Faber et al., 
2012a; Han et 
al., 2012) 
IEM T631C S211P RT -8.2 ↓ ↑ ↔ ↓ ↔     ↑   E    <15  (Estacion et 
al., 2010) 
IEM T647C F216S RT -11.8 ↓ ↑ ↔ ↓   -15.6   ↑  ↔ E  Y   exercise, heat, standing (Choi et al., 
2006; Drenth 
et al., 2005) 
 
IEM/SF
N 
C684G I228M 20 ↔ ↔ ↔ ↔    +6.8 
↑ 
↓   ↔ ↔ Jaw, 
teeth, 
myalgia 
Dry mouth, 
urinary, GI 
retention 
N  56 
32 
Heat, cold, physical 
activity 
(Estacion et 
al., 2011; 
Faber et al., 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
92 
 
2012a; Faber 
et al., 2012b) 
 
E, scalp Perspiration, 
urinary 
retention 
N  46  (Estacion et 
al., 2011) 
 
IEM T701C I234T RT -17.9 ↓ ↑ ↔ ↓   -21   ↑  ↔     1 Exercise, heat (Ahn et al., 
2010) 
 
IEM T721A S241T 21 -8.4 ↓ ↑ ↔    -12.3   ↑  ↓ E  Y  5-17 exercise, heat, standing (Lampert et 
al., 2006; 
McDonnell et 
al., 2016; 
Michiels et 
al., 2005) 
 
IEM C733G L245V RT ↔ 
(increas
ed 
slope) 
 ↑ ↔    -10   ↑ ↑ ↔ E  Y  ~10-
20 
Exercise, heat, infection (Emery et al., 
2015) 
 
IEM C1185A N395K 21 -7.7  ↑ ↔    +13.1      E  Y   exercise, heat, standing (Drenth et al., 
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2005; Sheets 
et al., 2007) 
 
IEM G1198A V400M 21 -6.5  ↑ +7.3 ↔   ↔   ↑   E  Y  1-10 exercise, heat, standing, 
cold (1) 
(Fischer et al., 
2009; 
McDonnell et 
al., 2016) 
 
IEM C1828A P610T               E  Y   exercise, heat, standing (Drenth et al., 
2005) 
Likely not 
causal (Klein 
et al., 2013; 
Samuels et al., 
2008) 
IEM G1846A G616R RT ↔   +5.7          E, face, 
ears 
 Y  6,8,2
4 
 (Choi et al., 
2010) 
SFN  D623N RT ↔   +4.5    +5.3   ↔   E, skin 
hyperesth
esia 
GI, OH, dry 
mouth 
    (Faber et al., 
2012a) 
SFN  I720K RT ↔   ↔    +8.8   ↔   E, skin Sweating,     (Faber et al., 
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hyperesth
esia 
dry mouth, 
micturition 
problems 
2012a) 
Idiopathi
c 
itch/SFN 
A2215G I739V 21 ↔ ↔  ↔    +5.6 
↑ 
↓ ↔  ↑   OH, flushing, 
sweating 
  15-
55 
Warmth, hot/spicy food (Devigili et 
al., 2014; 
Faber et al., 
2012a; Han et 
al., 2012) 
 
IEM  L823R RT -14.6 ↑ ↑ -9.8 ↑        ↔ E  Y  <2 warmth (Lampert et 
al., 2009; 
Takahashi et 
al., 2007) 
IEM  I848T; 
S449N 
              E    4 exercise, heat, standing (McDonnell et 
al., 2016) 
IEM T2543C I848T RT -13.8/-
4.9 
 ↑ ↔/-
2.2/+4.5 
↓ ↑   ↓  ↑  ↔ E  Y  3-15 Exercise, heat (Cummins et 
al., 2004; 
Drenth et al., 
2008; 
Natkunarajah 
et al., 2009; 
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Wu et al., 
2013; Yang et 
al., 2004) 
35 -0.6   +8.2          E      (Wu et al., 
2013) 
22 -9.5   +3.0 ↔     ↔          (Theile et al., 
2011) 
IEM G2567A G856D  -9.3  ↑ +6.2    -15.1   ↑ ↑ ↓ E, cheeks, 
ears 
Perspiration, 
GI, dry 
mouth, 
erectile 
dysfunction 
Y  10 Warmth, exercise, 
alcohol 
(Hoeijmakers 
et al., 2012) 
IEM T2573A L858H 21 -13.3  ↑ -2.5 ↓   ~-40  ↔ ↑   E  Y  4-8 Exercise, heat (Cummins et 
al., 2004) 
22 -4   -1.5 ↓         (Theile et al., 
2011) 
IEM C2572T 
 
L858F 21 -9  ↑ +3 ↔ ↑     ↑  ↔ E  P  2 exercise, heat (Drenth et al., 
2005; Han et 
al., 2006) 
16 -4.7  ↑ ↔       ↑  ↔ (Han et al., 
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2007) 
35 -8.9  ↑ +3       ↑  ↔ (Han et al., 
2007) 
IEM G2587C A863P RT -7.7  ↑ +9.8 ↔ ↑   ↑  ↑  ↓ E    <6  (Harty et al., 
2006) 
IEM  V872G RT -9.3   ↔    ↓   ↑   E  Y  5 warmth, 
excerise 
(Choi et al., 
2009) 
IEM C2623G Q875E  -17.5 ↓F ↑ ↔ ↓   +22.8      E AH, AVD Y  2 Warmth, mechanical 
stimuli, exertion, stress, 
weight-bearing 
(Skeik et al., 
2012; Stadler 
et al., 2015) 
 
SFN  M932L/V99
1L 
RT ↔  ↔ ↔ 
 
  ↔  ↑ ↔   E, skin 
hyperesth
esia 
Sweating, 
dry mouth 
    (Faber et al., 
2012a) 
IEM 2863_2865
del TTA 
Del-L955 22 -24.2  ↑ 
(> 
5 
mV
) /↓  
-2.9 ↑ (> 
-15 
mV)/
↓  
  -39   ↑ ↑ ↔ E, nose, 
ear, chin 
 Y  15 Warmth, exercise, 
freight, 
pressure/standing 
(Cheng et al., 
2011) 
PEPD  R996C                     (Fertleman et 
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al., 2006) 
IEM C3448T R1150W RT -7.9   ↔    ↔      E  Y   exercise, heat, standing (Drenth et al., 
2005; 
Estacion et al., 
2009) 
allele present 
at 17.58% 
frequency, 
likely non-
causal 
(Holliday et 
al., 2012; 
Klein et al., 
2013) 
Distal 
limb pain 
G3836C R1279P 22 +5.9   +9.6 ↑ ↑  +7.6   ↑  ↔  Palpitations, 
hot and cold 
flushes, cold 
fingers 
  33  (Huang et al., 
2014) 
PEPD  V1298D                     (Fertleman et 
al., 2006) 
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PEPD  V1298F 21 +6.3  ↔ +19.8 ↑ ↑ ↓    ↑ ↑ ↓       (Jarecki et al., 
2008) 
PEPD  V1299F 22 +1.7/+4.
5 
 ↔ +13.1/+
21 
↑ ↑ ↓   ↑ ↑  ↔       (Jarecki et al., 
2008; Theile 
et al., 2011) 
IEM  P1308L RT -9.6   ↔    ↔   ↑   E  Y  2 Warmth (Cheng et al., 
2010) 
IEM T3947C V1316A RT -6.8   +3.1  ↑        E    7  (Wu et al., 
2013) 35 -7.3   +4.8          
IEM  F1449V 21 -7.6/-7.2 ↓ ↔ +4.3 ↓ ↑  ~-20   ↔         (Dib-Hajj et 
al., 2005; 
Lampert et al., 
2008) 
PEPD  I1461T 21 +2.5 
↔ 
 
 ↔ +18.8 ↑ ↑ ↓   ↑ ↑ ↑ ↔       (Fertleman et 
al., 2006; 
Jarecki et al., 
2010; Jarecki 
et al., 2009) 
PEPD  F1462V                     (Fertleman et 
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al., 2006) 
PEPD  T1464I 22 +0.9   +6.7 ↑     ↑          (Fertleman et 
al., 2006; 
Theile et al., 
2011) 
SFN  M1532I RT ↔   ↔    ↑   ↔         (Faber et al., 
2012a) 
IEM T4612C W1538R RT -8.6 ↔  +2.3  ↔   +2.
4 
  ↔  E - Y  61 Heat, standing, footwear (Cregg et al., 
2013) 
PEPD G4819C G1607R  +4.3   +31.5       ↑ ↑  rectum Sweating, 
harlequin 
erythema 
 Y <1 Defecation, mechanical 
stimulation  
(Choi et al., 
2011) 
PEPD T4835C L1612P 25 +9.0   +30.9 ↑ ↑  ↔   ↑ ↔ ↔ Rectum, 
ocular, 
submandi
bular, 
upper 
limbs 
 Y  <1 Light touch, trauma, 
defecation, warmth 
(Suter et al., 
2015) 
PEPD T4879A M1627K 22 +1.6 
+2.9 
 ↔ +20.2 
+19.3 
↑  ↓ ↔  ↑ ↑  ↓ Lower 
limbs 
   <1 Defecation, noxious 
stimuli 
(Dib-Hajj et 
al., 2008a; 
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Fertleman et 
al., 2006; 
Theile et al., 
2011) 
IEM/PE
PD 
C4895A A1632E RT -7.1 ↑ 
S 
↑ +17 ↑ ↑  ↔ 
Slope 
increas
ed 
 ↑ ↑ ↑ ↓ Eye, jaw, 
face, E 
Apnea, 
bradycardia, 
GI 
Y  <1 Eating, voiding, bowel 
movement, warmth 
(Eberhardt et 
al., 2014; 
Estacion et al., 
2008) 
Note: 
combines 
features of 
PEPD and 
IEM 
 
IEM C4895G A1632G RT -7   +9    ↔ 
 
 ↓    E    5-12 Warmth, excersise (Yang et al., 
2016) 
IEM G4894A A1632T RT ↔ ↔ ↓ 
F 
+7.3 ↔ 
 
  ↔ 
 
 ↔ 
 
↑ ↔ 
 
↔ E    3-17 Warmth, exercise, 
footwear, alcohol 
(Eberhardt et 
al., 2014) 
IEM C5237G A1746G RT -15.6 ↔  +1.4  ↑  +2.3    ↔  E - Y  3 Exercise, standing, heat, 
footwear 
(Cregg et al., 
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2013) 
Table 4. Effect of NaV1.7 knockout on physiology and mouse behaviours. Abbreviations: # survival possible with hand-feeding; ↓ - 
decreased/attenuated pain behaviours; ↑ - increased; ↔ - normal/unchanged pain behaviours; Lost – complete absence of pain behaviours 
consistent with insensitivity to pain 
 
 Nav1.7Nav1.8 Nav1.7Advil  
 
Nav1.7Wnt1 
 
Nav1.7OSM Nav1.7ADERT2 NaV1.7Agrp NaV1.7Pomc NaV1.7PVH Global  
Affected cells NaV1.8-
positive 
nociceptors 
All 
sensory 
neurons 
Cells 
originating 
from dorsal 
neural tube 
olfactory 
sensory 
neurons 
Tamoxifen-
inducible loss 
in advillin-
positive 
neurons 
Agrp-expressing 
neurons in 
hypothalamic 
arcuate nucleus 
Pomc-
expressing 
neurons 
PVH-
expressing 
neurons 
all 
Reference (Nassar et 
al., 2004) 
(Minett et 
al., 2012) 
(Minett et 
al., 2012) 
(Weiss et 
al., 2011) 
(Minett et al., 
2012) 
(Branco et al., 
2016) 
(Branco et 
al., 2016) 
(Branco et 
al., 2016) 
(Gingras et 
al., 2014) 
 Physiological effects 
Olfaction    Lost     Lost 
Body weight ↔ ↔ ↔ ↓   ↓ ↑ ↑ ↓↓↓#  
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 Acute nociception 
Acute heat 
(Hargreaves/Hot 
Plate) 
↔ ↔ Lost      Lost 
Acute mechanical  Lost Lost Lost      Lost 
Acute cold 
(acetone) 
↔ ↓ ↓       
Temperature 
Preference 
↔ ↔ ↔       
 Inflammatory pain 
Formalin Phase I ↓ ↓ ↓      ↓ 
Formalin Phase II  ↓ ↓ ↓      ↓ 
CFA thermal 
hyperalgesia  
Lost         Lost 
CFA mechanical  Lost(Nassar 
et al., 2004) 
↔(Shields 
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et al., 2012)  
Burns thermal Lost(Shields 
et al., 2012) 
        
Burns mechanical  ↔(Shields 
et al., 2012) 
        
Carrageenan 
thermal  
Lost         
NGF thermal ↓         
 Neuropathic pain 
SNT mechanical ↔ ↔ Lost       
SNT cold  ↔ ↔ Lost       
CCI mechanical  ↔ ↓ Lost  ↓     
CCI cold  ↓ ↓ Lost       
Oxaliplatin 
mechanical 
  ↔       
Oxaliplatin cold   ↔       
Cancer-induced   ↔       
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bone pain 
 Toxin-induced pain 
Veratridine         ↓ 
Grayanotoxin III          ↓ 
OD1  ↓(Deuis et 
al., 2014) 
       
 
 
Table 5. Percent identity matrix of human NaV isoforms  
The table displays the percentage of identical amino acids between all nine human voltage-gated sodium channel α-subunits for the whole amino 
acid sequences. Sequence identities with hNaV1.7 are highlighted in grey. Multiple sequence alignment was performed using Clustal Omega 
1.2.2 with default parameters. We used the amino acid sequences in the canonical isoform 1 as provided by the UniProtKB database 
(http://www.uniprot.org/). UniProtKB entry identifiers: P35498 (SCN1A, hNaV1.1); Q99250 (SCN2A, hNaV1.2); Q9NY46 (SCN3A, hNaV1.3); 
P35499 (SCN4A, hNaV1.4); Q14524 (SCN5A, hNaV1.5); Q9UQD0 (SCN8A, hNaV1.6); Q15858 (SCN9A, hNaV1.7); Q9Y5Y9 (SCN10A, 
hNaV1.8); Q9UI33 (SCN11A, hNaV1.9). All values are in percent. 
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Isoform hNaV1.1 hNaV1.2 hNaV1.3 hNaV1.4 hNaV1.5 hNaV1.6 hNaV1.7 hNaV1.8 hNaV1.9 
hNaV1.1 100.00 87.90 84.74 71.17 64.95 77.62 77.50 58.55 52.65 
hNaV1.2 87.90 100.00 87.67 71.94 65.78 77.17 78.80 59.06 53.67 
hNaV1.3 84.74 87.67 100.00 70.74 66.04 76.10 77.22 58.92 53.29 
hNaV1.4 71.17 71.94 70.74 100.00 67.37 70.35 70.18 61.02 52.97 
hNaV1.5 64.95 65.78 66.04 67.37 100.00 65.33 63.66 64.73 55.50 
hNaV1.6 77.62 77.17 76.10 70.35 65.33 100.00 72.41 59.18 53.03 
hNaV1.7 77.50 78.80 77.22 70.18 63.66 72.41 100.00 58.24 53.50 
hNaV1.8 58.55 59.06 58.92 61.02 64.73 59.18 58.24 100.00 54.61 
hNaV1.9 52.65 53.67 53.29 52.97 55.50 53.03 53.50 54.61 100.00 
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Table 6. NaV1.7 sequence identity in selected sequence domains relevant for modulator interaction 
The table shows the percentage of identical amino acids between the human NaV1.7 and each of the other eight human NaV α-subunit isoforms 
for selected amino acid sequence domains that are relevant for known modulator interactions. Sequence alignment was performed as described 
above using the same sequences. The used boarders of transmembrane segments and intra- and exctacellular domains are as defined by the 
UniProtKB database. All values are shown in percent. 
Sequences: VSD: start of S1 – end of S4; PD: start of S5 – end of S6; DI P-loop: amino acid positions (AA pos.) 355-366 (in SCN9A, and 
corresponding aligned positions in all other isoforms); DII P-loop: AA pos. 921-931 (in SCN9A); DIII P-loop: AA pos. 1400-1411 (in SCN9A); 
DIV P-loop: AA pos. 1692-1703 (in SCN9A); DI S1+linker+S2: AA pos. 139-162 (in SCN9A); DII S1+linker+S2: AA pos. 756-785 (in 
SCN9A); DIII S1+linker+S2: AA pos. 1205-1235 (in SCN9A); DIV S1+linker+S2: AA pos. 1527-1555 (in SCN9A); DI S3+linker+S4: AA pos. 
197-221 (in SCN9A); DII S3+linker+S4: AA pos. 818-842 (in SCN9A); DIII S3+linker+S4: AA pos. 1268-1293 (in SCN9A); DIV 
S3+linker+S4: AA pos. 1589-1619 (in SCN9A). 
Percent-identity compared to hNaV1.7 
<70 ≥70 ≥80 ≥90 
 
Selected sequence 
domains 
hNaV1.1 hNaV1.2 hNaV1.3 hNaV1.4 hNaV1.5 hNaV1.6 hNaV1.8 hNaV1.9  Identity 
between all 9 
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sequences 
DI VSD 90.00 90.00 90.00 83.33 83.64 86.36 64.49 54.63 40.000 
DII VSD 85.09 83.33 84.21 89.38 73.68 86.84 67.54 61.06 49.573 
DIII VSD 86.32 85.47 87.18 83.76 83.76 82.91 72.65 64.55 48.718 
DIV VSD 82.64 85.12 80.99 76.86 69.42 80.17 61.98 53.72 44.715 
DI PD 75.80     75.16   72.61 73.89 69.48 74.00 64.90 55.10 31.527 
DII PD 94.00 93.00 97.00 92.00 79.59 96.00 65.00 59.00 42.202 
DIII PD 77.61 79.85 76.34 77.44 70.68 72.39 70.45 64.84 51.095 
DIV PD 93.86 92.98 92.98 83.33 74.34 84.96 71.68 66,67 50.877 
DI S5-S6 linker 64.76    64.76    63.81    62.62    57.84    62.86   55.79    44.57 20.395 
DII S5-S6 linker 92.45    90.57    98.11    90.38    70.59    94.34   56.60    54.72 34.426 
DIII S5-S6 linker 65.82    69.62    64.47    65.38    53.85    60.76   57.69    53.42 36.364 
DIV S5-S6 linker 90.91    89.39    89.39    80.30    67.69    81.54   66.15    56.14 40.909 
DI S1-S2 linker 87.50    87.50    87.50    50.00    62.50    75.00   20.00    14.29 0 
DII S1-S2 linker 63.64    63.64    63.64    72.73    54.55    63.64   45.45    45.45 36.364 
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DIII S1-S2 linker 69.23    76.92    76.92    53.85    69.23    69.23   46.15    30.77 14.286 
DIV S1-S2 linker 36.36    54.55    36.36    36.36    27.27    36.36   36.36    27.27 18.182 
DI S3-S4 linker 83.33    83.33    83.33    66.67    83.33   100.00   33.33     0.00 0 
DII S3-S4 linker 83.33    83.33    83.33    66.67    33.33   100.00   33.33    16.67 12.5 
DIII S3-S4 linker 75.00    75.00    75.00    75.00    25.00    75.00   50.00     0.00 0 
DIV S3-S4 linker 90.00    90.00    90.00    77.78    70.00    90.00   50.00    44.44 25 
DI P-loop 91.67    91.67   100.00   100.00    83.33   100.00   83.33    83.33 83.333 
DII P-loop 100.00   100.00   100.00    90.91    90.91   100.00   81.82    81.82 81.818 
DIII P-loop 83.33 83.33 83.33 83.33 83.33 83.33 83.33 83.33 83.333 
DIV P-loop 100.00 100.00 100.00 91.67 100.00 100.00 100.00 83.33 75 
DI S1+linker+S2 91.67 91.67 87.50    79.17    66.67    83.33   47.62    41.67 25 
DII S1+linker+S2 80.00    80.00    80.00    83.33    70.00    83.33   60.00 60.00    46.667 
DIII S1+linker+S2 80.65    83.87    83.87    77.42    80.65    83.87   58.06    48.39 35.484 
DIV S1+linker+S2 62.07    75.86    65.52    62.07    51.72    65.52   51.72    41.38 34.483 
DI S3+linker+S4 88.00    88.00    88.00    84.00    84.00    88.00   52.00    39.13 32.143 
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DII S3+linker+S4 92.00    88.00    84.00    88.00    72.00    92.00   68.00    40.00 33.333 
DIII S3+linker+S4 80.77    80.77    84.62    80.77    80.77    80.77   57.69    47.37 23.077 
DIV S3+linker+S4 93.55    93.55    90.32    83.87    77.42    93.55   54.84    54.84 42.424 
DI S6 96.15    96.15    92.31    96.15    88.46    88.46   88.46    80.77 65.385 
DII S6 92.31    92.31    92.31    88.46    80.77    96.15   73.08    65.38 53.846 
DIII S6 92.59    92.59    92.59    92.59    96.30    92.59    81.48    88.89 74.074 
DIV S6 96.00    96.00    96.00    80.00    76.00    88.00   76.00    84.00 64 
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Table 7. NaV1.7 selectivity of antibodies, peptides and small molecules. The in vitro IC50 at NaV1.7 is shown in blue. Selectivity over NaV1.1-
NaV1.9, expressed as fold-selectivity over NaV1.7, is color-coded as indicated below. Abbreviations and symbols: EP – Whole cell patch-clamp 
electrophysiology in mammalian expression systems (CHO, HEK293 cells); TEVC – Two electrode Voltage-Clamp electrophysiology in 
Xenopus oocytes; MP – fluorescent membrane potential dye assay in mammalian expression systems (CHO, HEK293 cells); ? – not specified; # 
- activator/agonist; h – human; r – rat; m – mouse; β1, β2, β3, β4 – co-expressed β subunits. 
Fold-selectivity over NaV1.7 
 
<3 
>3 
<10 
>10 
<30 
>30 
<100 
>100 
<300 
>300 
<1000 
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Proteins/peptides 
Antibodies 
SVMab1 - h r h h m m h r ?  EP (Lee et al., 2014) 
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205 293 290 263 186 210 30.7 
nM 
169 
Cone snail venom peptides 
µ-conotoxin 
KIIIA 
CCNCSSKWCRDHSR
CC-NH2 
r r r r r m r r/β1 ?  TEV
C 
(Wilson et al., 2011) 
1 0.02 28 0.3 989 0.8 290 
nM 
>344 
µ-conotoxin 
SmIIIA 
ZRCCNGRRGCSSRW
CRDHSRCC 
r r r r r m r r/β1 ?  TEV
C 
(Wilson et al., 2011) 
0.003 0.001 0.03 0.000
1 
1 0.12 1300 
nM 
>77 
Spider venom peptides 
β/ω-
theraphotoxin-
Tp2a (ProTxII) 
YCQKWMWTCDSER
KCCEGMVCRLWCK
KKLW 
? h/β1 h ? h h h/β1 h/β1 ? CaV3.1 EP (Schmalhofer et al., 2008) 
136 343 130 263 86 0.3 
nM 
486 
ω-
theraphotoxin-
Gr2a 
(GpTx-1, 
GTx1-15) 
DCLGFMRKCIPDND
KCCRPNLVCSRTHK
WCKYVF-NH2 
 
 
? ? h h h ? h h ?  EP (Murray et al., 2015) 
4.6 30 >55 90 
nM 
2772 
h/β1 h/β1 h/β1 h/β1 h/β1 h/β1 h/β1 h ?  MP (Deuis et al., 2016) 
9 4 38 457 239 24 537 
nM 
60 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
112 
 
R18K-GpTx-1 DCLGFMRKCIPDND
KCCKPNLVCSRTHK
WCKYVF-NH2 
? ? ? h h ? h ? ?  EP (Murray et al., 2016) 
318 9937 1.6 
nM 
µ-
theraphotoxin-
Hs2a 
(Huwentoxin-4) 
ECLEIFKACNPSNDQ
CCKSSKLVCSRKTR
WCKYQI 
? r r r h  h      
5.8 13 15 >385 ? 26 
nM 
? ?  EP (Xiao et al., 2008) 
µ-
theraphotoxin-
Hhn1b 
(Hainantoxin-
IV) 
ECLGFGKGCNPSND
QCCKSSNLVCSRKH
RWCKYEI 
 r r r h  h      
? 1.7 18 >476 >476 ? 21 
nM 
? ?  EP (Cai et al., 2015) 
µ-
theraphotoxin-
Phlo1a 
ACRELLGGCSKDSD
CCAHLECRKKWPY
HCVWDWTI 
? r ? ? h ? h ? ?  TEV
C 
(Chow et al., 2015) 
>2.2 >2.2 459 
nM 
µ-
theraphotoxin-
Phlo1b 
ACRELLGGCSKDSD
CCAHLECRKKWPY
HCVWDWTF 
? r ? ? h ? h ? ?  TEV
C 
(Chow et al., 2015) 
>2.8 >2.8 360 
nM 
µ- SCQKWMWLCDEER ? r ? ? h ? h ? ?  TEV (Chow et al., 2015) 
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theraphotoxin-
Phlo2a (Phlo2a) 
KCCEDMVCKLWCK 1.2 0.65 333 
nM 
C 
ω-
theraphotoxin-
Gr2a 
DCLGFMRKCIPDND
KCCRPNLVCSRTHK
WCKYVF 
? ?    ?  ? ?    
2.3 392 1202 7.4 
nM 
µ-
theraphotoxin-
Tp1a (ProTxIII) 
DCLKFGWKCNPRN
DKCCSGLKCGSNHN
WCKLHI-NH2 
h/β1 h/β1 h/β1 h/β1 h/β1 h h/β1 h ?  MP (Cardoso et al., 2015) 
 2.3 1.4 4.1 >22 >22 1.3 220 
nM 
>22 
β/ω-
theraphotoxin-
Tp1a (ProTxI) 
ECRYWLGGCSAGQT
CCKHLVCSRRHGW
CVWDGTFS 
? ? ? ? ? ? h r r KV2.1, 
CaV3.1, 
TRPA1 
TEV
C 
(Gilchrist and Bosmans, 
2012; Gui et al., 2014; 
Middleton et al., 2002) 
 
<2 <2 51 
nM 
0.5 ? # 
β-
theraphotoxin-
Gr1a (GrTx1) 
YCQKWMWTCDSKR
KCCEDMVCQLWCK
KRL 
h h h h h h h ? ? KV11.1  (Redaelli et al., 2010) 
 1.7 0.6 2 3.5 60 1.7 370 
nM 
β-
theraphotoxin-
Gr1b 
(GsAF-I) 
YCQKWLWTCDSER
KCCEDMVCRLWCK
KRL 
h h h h h h h ? ? KV11.1  (Redaelli et al., 2010) 
 9 15 32 8 1000 30 40 
nM 
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Centipede venom peptides 
µ-SLPTX-
Ssm6a 
ADNKCNSLRREIAC
GQCRDKVKTDGYF
YECCTSDSTFKKCQ
DLLH 
      inacti
ve 
   EP (Murray et al., 2015; Yang 
et al., 2013) 
Small molecules 
PF-05089771 
(clinical 
candidate)  
h h h h h h h h ?  EP (Alexandrou et al., 2016) 
77 10 1000 909 2272 14.5 11 
nM 
>909 
h h h h h h h h ?  EP (Cao et al., 2016) 
 61.5 10.8 >909 >909 >909 15.7 11 
nM 
>909 
PF-05198007 
 
h h h h h h h h ?  EP (Alexandrou et al., 2016) 
33.5 ? ? ? ? 28.6 5.2 
nM 
? 
PF-05153462 
 
h h h h h h h h ?  EP (Cao et al., 2016) 
82 134 246 246 820 138 12.2 
nM 
>82 
PF-04856264 ? ? h ? h ? 28 ? ?  EP (McCormack et al., 2013) 
O
S
N
H
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S
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F
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>357 >357 nM  
h/β1 h/β1 h/β1 h/β1 h/β1 h/β1 h/β1 h ?  MP (Deuis et al., 2016) 
 823 67 >1000 >1000 >1000 >1000 300 
nM 
>1000 
GDC-0276 Not disclosed h h ? ? h h h ? ?  EP  (Butler and Finn, 2009) 
 28 50 123 1200 0.4 
nM 
Cpd 3 
 
h/β1 h/β1 ? ? h/β1 h/β1 h/β1 ? ?  EP (Focken et al., 2016) 
 7700 10.5 3450 27.5 0.4 
nM 
Cpd 16 
 
h/β1 h/β1 h/β1 h/β1 h/β1 h/β1 h/β1 h/ β3 ?  EP (Focken et al., 2016) 
 >10,0
00 
0.7 >10,0
00 
>10,0
00 
>10,0
00 
2.7 0.3 
nM 
3850 
GX-674 
 
h h/β1 h/β1 h/β1 h/β1 h h/β2 h/β3 ?  EP (Ahuja et al., 2015) 
~10,0
00 
~1 > 
10,00
0 
> 
10,00
0 
> 
10,00
0 
~6 0.1 
nM 
>10,0
00 
TV-45070 
(XEN402, 
 
? ? ? ? ? ? h ? ?  ? (Goldberg et al., 2012) 
 80 
N
H
N
O
S NH
N
N
S
H2N
Cl
F
F
O
O
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funapide) nM 
CNV1014802 
(Raxatrigine, 
GSK-1014802) 
 
h/β1 h/β1 h/β1 h/β1 h/β1 h/β1 h/β1 h ?  MP (Deuis et al., 2016) 
0.7 0.4 0.7 0.3 2.6 0.5 32 
µM 
0.2 
Compound 52 
 
? ? h h h ? h r ?  EP (Bregman et al., 2011) 
1.7 2.3 6.5 170 
nM 
12.9 
BZP 
 
? ? ? ? h/β1 ? h/β1 h/β1 ?  MP (Williams et al., 2007) 
6 300 
nM 
10 
Compound 41 
(Merck)  
? ? ? ? h ? h ? ?  MP (Ho et al., 2014) 
64 9 nM 
Compound 30 
(Merck) 
 
 
? ? ? ? h ? h ? ?  EP (Hoyt et al., 2013) 
 5.4 8.8 440 
nM 
6.8 
 
 
H
N
O
F
H2N
O
N
N
H
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O
F
O O F
F3C
F
F
